Revance Therapeutics (RVNC) 10-Q 8 Nov 23 2023 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2023	Oct. 31, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	001-36297
Entity Registrant Name	Revance Therapeutics, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	77-0551645
Entity Address, Address Line One	1222 Demonbreun Street, Suite 2000
Entity Address, City or Town	Nashville
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37203
City Area Code	615
Local Phone Number	724-7755
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	RVNC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		87,813,480
Entity Central Index Key	0001479290
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
CURRENT ASSETS
Cash and cash equivalents	$ 179,319	$ 108,965
Restricted cash, current	275	0
Short-term investments	120,926	231,742
Accounts receivable, net	25,414	11,339
Inventories	46,214	18,325
Prepaid expenses and other current assets	16,371	4,356
Total current assets	388,519	374,727
Property and equipment, net	17,179	13,799
Goodwill	0	77,175
Intangible assets, net	10,507	35,344
Operating lease right-of-use assets	54,810	39,223
Finance lease right-of-use asset	23,209	6,393
Restricted cash, non-current	7,145	6,052
Finance lease prepaid expense	30,883	27,500
Other non-current assets	235	1,687
TOTAL ASSETS	532,487	581,900
CURRENT LIABILITIES
Accounts payable	4,775	4,546
Accruals and other current liabilities	53,493	59,357
Deferred revenue, current	5,371	6,867
Finance lease liability, current	8,610	669
Operating lease liabilities, current	8,659	4,243
Debt, current	1,250	0
Total current liabilities	82,158	75,682
Debt, non-current	427,101	379,374
Deferred revenue, non-current	84,315	78,577
Operating lease liabilities, non-current	42,279	34,182
Other non-current liabilities	2,835	1,485
TOTAL LIABILITIES	638,688	569,300
Commitments and Contingencies (Note 12)
STOCKHOLDERS’ EQUITY (DEFICIT)
Preferred stock, par value $0.001 per share — 5,000,000 shares authorized, and no shares issued and outstanding as of September 30, 2023 and December 31, 2022	0	0
Common stock, par value $0.001 per share — 190,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 87,813,315 and 82,385,810 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	88	82
Additional paid-in capital	1,916,385	1,767,266
Accumulated other comprehensive loss	(13)	(374)
Accumulated deficit	(2,022,661)	(1,754,374)
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)	(106,201)	12,600
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	$ 532,487	$ 581,900

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock authorized (in shares)	190,000,000	190,000,000
Common stock, shares issued (in shares)	87,813,315	82,385,810
Common stock, shares outstanding (in shares)	87,813,315	82,385,810

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue:
Total revenue	$ 56,776	$ 29,015	$ 164,241	$ 82,644
Operating expenses:
Selling, general and administrative	69,094	65,775	212,489	158,697
Research and development	13,060	26,103	59,044	81,745
Goodwill impairment	77,175	0	77,175	0
Intangible asset impairment	16,007	0	16,007	0
Depreciation and amortization	1,320	3,885	5,459	11,597
Total operating expenses	196,069	106,499	427,065	280,191
Loss from operations	(139,293)	(77,484)	(262,824)	(197,547)
Interest income	3,733	1,165	9,851	1,860
Interest expense	(5,093)	(6,917)	(13,958)	(12,722)
Other expense, net	(223)	(757)	(1,056)	(1,361)
Loss before income taxes	(140,876)	(83,993)	(267,987)	(209,770)
Income tax provision	(300)	(700)	(300)	(700)
Net loss	(141,176)	(84,693)	(268,287)	(210,470)
Unrealized gain (loss)	48	(74)	361	(442)
Comprehensive loss	(141,128)	(84,767)	(267,926)	(210,912)
Basic net loss	(141,176)	(84,693)	(268,287)	(210,470)
Diluted net loss	$ (141,176)	$ (84,693)	$ (268,287)	$ (210,470)
Basic net loss (in dollars per share)	$ (1.63)	$ (1.17)	$ (3.20)	$ (3)
Diluted net loss (in dollars per share)	$ (1.63)	$ (1.17)	$ (3.20)	$ (3)
Basic weighted-average number of shares used in computing net loss per share (in shares)	86,613,425	72,208,285	83,816,577	70,215,148
Diluted weighted-average number of shares used in computing net loss per share (in shares)	86,613,425	72,208,285	83,816,577	70,215,148
Product revenue
Revenue:
Total revenue	$ 54,109	$ 26,081	$ 154,160	$ 72,401
Operating expenses:
Cost of product revenue /service revenue (exclusive of amortization of intangible assets)	16,821	8,681	46,915	24,130
Service revenue
Revenue:
Total revenue	2,664	1,964	9,942	4,046
Operating expenses:
Cost of product revenue /service revenue (exclusive of amortization of intangible assets)	2,592	2,055	9,976	4,022
Collaboration revenue
Revenue:
Total revenue	$ 3	$ 970	$ 139	$ 6,197

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders’ Equity (Deficit) - USD ($) $ in Thousands	Total	Preferred Stock	Common Stock	Common Stock At the Market Offering	Additional Paid-In Capital	Other Accumulated Comprehensive Loss	Accumulated Deficit
Beginning Balance (in shares) at Dec. 31, 2021			71,584,057		0	0	0
Beginning Balance at Dec. 31, 2021			$ 72		$ 1,466,369	$ (18)	$ (1,397,952)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock related to ATM, net of commissions and issuance costs (in shares)				1,734,853
Issuance of common stock related to ATM, net of commissions and issuance costs				$ 1	31,554
Issuance of common stock upon exercise of stock options (in shares)			122,377
Issuance of common stock upon exercise of stock options					621
Issuance of common stock relating to 2014 ESPP (in shares)			171,824
Issuance of common stock related to 2014 ESPP					2,018
Shares withheld related to net settlement of restricted stock awards (in shares)			(268,632)
Shares withheld related to net settlement of stock awards					(4,613)
Cancellation of stock awards, net of issuance (in shares)			(257,611)
Issuance of common stock in connection with follow-on offering, net of underwriting discounts, commissions, and offering costs (in shares)			9,200,000
Issuance of common stock in connection with follow-on offering, net of underwriting discounts, commissions, and offering costs			$ 9		215,921
Stock-based compensation	$ 42,295
Other					$ 348
Unrealized gain (loss)	(442)					$ (442)
Net loss	$ (210,470)						$ (210,470)
Ending Balance (in shares) at Sep. 30, 2022	82,286,868	0	82,286,868		0	0	0
Ending Balance at Sep. 30, 2022	$ 145,713	$ 0	$ 82		$ 1,754,513	$ (460)	$ (1,608,422)
Beginning Balance (in shares) at Jun. 30, 2022			73,123,363		0	0	0
Beginning Balance at Jun. 30, 2022			$ 73		$ 1,521,411	$ (386)	$ (1,523,729)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock related to ATM, net of commissions and issuance costs					(31)
Issuance of common stock upon exercise of stock options (in shares)			91,743
Issuance of common stock upon exercise of stock options					512
Shares withheld related to net settlement of restricted stock awards (in shares)			(83,486)
Shares withheld related to net settlement of stock awards					(1,853)
Cancellation of stock awards, net of issuance (in shares)			(44,752)
Issuance of common stock in connection with follow-on offering, net of underwriting discounts, commissions, and offering costs (in shares)			9,200,000
Issuance of common stock in connection with follow-on offering, net of underwriting discounts, commissions, and offering costs			$ 9		215,921
Stock-based compensation					$ 18,553
Unrealized gain (loss)	(74)					$ (74)
Net loss	$ (84,693)						$ (84,693)
Ending Balance (in shares) at Sep. 30, 2022	82,286,868	0	82,286,868		0	0	0
Ending Balance at Sep. 30, 2022	$ 145,713	$ 0	$ 82		$ 1,754,513	$ (460)	$ (1,608,422)
Preferred stock, shares outstanding (in shares)	0
Beginning Balance (in shares) at Dec. 31, 2022	82,385,810		82,385,810		0	0	0
Beginning Balance at Dec. 31, 2022	$ 12,600		$ 82		$ 1,767,266	$ (374)	$ (1,754,374)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock related to ATM, net of commissions and issuance costs (in shares)				3,223,767
Issuance of common stock related to ATM, net of commissions and issuance costs				$ 3	99,956
Issuance of common stock related to stock awards (in shares)			1,795,729
Issuance of common stock related to stock awards			$ 2		(2)
Issuance of common stock upon exercise of stock options (in shares)			694,300
Issuance of common stock upon exercise of stock options			$ 1		11,573
Issuance of common stock relating to 2014 ESPP (in shares)			157,313
Issuance of common stock related to 2014 ESPP					2,455
Shares withheld related to net settlement of restricted stock awards (in shares)			(337,331)
Shares withheld related to net settlement of stock awards					(8,068)
Cancellation of stock awards, net of issuance (in shares)			(106,273)
Stock-based compensation					43,175
Other					$ 30
Unrealized gain (loss)	361					$ 361
Net loss	$ (268,287)						$ (268,287)
Ending Balance (in shares) at Sep. 30, 2023	87,813,315	0	87,813,315		0	0	0
Ending Balance at Sep. 30, 2023	$ (106,201)	$ 0	$ 88		$ 1,916,385	$ (13)	$ (2,022,661)
Beginning Balance (in shares) at Jun. 30, 2023			87,949,987			0	0
Beginning Balance at Jun. 30, 2023			$ 88		1,908,244	$ (61)	$ (1,881,485)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock related to stock awards (in shares)			75,419
Issuance of common stock upon exercise of stock options (in shares)			23,076
Issuance of common stock upon exercise of stock options					58
Shares withheld related to net settlement of restricted stock awards (in shares)			(200,387)
Shares withheld related to net settlement of stock awards					(3,774)
Cancellation of stock awards, net of issuance (in shares)			(34,780)
Stock-based compensation					$ 11,857
Unrealized gain (loss)	48					$ 48
Net loss	$ (141,176)						$ (141,176)
Ending Balance (in shares) at Sep. 30, 2023	87,813,315	0	87,813,315		0	0	0
Ending Balance at Sep. 30, 2023	$ (106,201)	$ 0	$ 88		$ 1,916,385	$ (13)	$ (2,022,661)
Preferred stock, shares outstanding (in shares)	0

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (268,287)	$ (210,470)
Adjustments to reconcile net loss to net cash used in operating activities:
Goodwill and intangible asset impairment	93,182	0
Stock-based compensation	38,968	41,613
Depreciation and amortization	9,956	16,266
Amortization of finance lease right-of-use asset	2,318	4,502
Amortization of debt discount and debt issuance costs	1,639	1,373
Amortization of discount on investments	(5,134)	(399)
Other non-cash operating activities	572	1,265
Changes in operating assets and liabilities:
Accounts receivable	(14,075)	(8,384)
Inventories	(18,068)	(6,606)
Prepaid expenses and other current assets	(12,015)	(947)
Lease right-of-use assets	(39,368)	(10,705)
Other non-current assets	1,000	(297)
Accounts payable	(127)	(9,711)
Accruals and other liabilities	(6,289)	3,928
Deferred revenue	4,242	4,222
Lease liabilities	36,292	10,984
Other non-current liabilities	1,350	0
Net cash used in operating activities	(173,844)	(163,366)
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from maturities of investments	295,782	161,183
Purchases of investments	(179,922)	(321,199)
Purchases of property and equipment	(5,107)	(1,922)
Finance lease prepayments	(3,383)	(17,820)
Net cash provided by (used in) investing activities	107,370	(179,758)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock in connection with ATM, net of commissions	100,183	31,814
Proceeds from issuance of notes payable, net of debt discount	48,415	98,150
Proceeds from the exercise of stock options and employee stock purchase plan	14,028	2,639
Principal payments on finance lease obligations	(15,513)	(5,000)
Taxes paid related to net settlement of stock awards	(8,068)	(4,613)
Payment of debt issuance costs and offering costs	(849)	(1,671)
Proceeds from issuance of common stock in connection with follow-on offering, net of discounts and commissions	0	216,200
Other financing activities	0	348
Net cash provided by financing activities	138,196	337,867
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH	71,722	(5,257)
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — Beginning of period	115,017	115,669
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — End of period	$ 186,739	$ 110,412

The Company and Summary of Sign

The Company and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company and Summary of Significant Accounting Policies	The Company and Summary of Significant Accounting Policies Overview Revance is a biotechnology company focused on developing and commercializing innovative aesthetic and therapeutic offerings. Revance’s portfolio includes DAXXIFY ® (DaxibotulinumtoxinA-lanm) for injection and the RHA ® Collection of dermal fillers in the U.S. Revance has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Shanghai Fosun Pharmaceutical to commercialize DAXXIFY ® in China. Liquidity and Financial Condition We are not profitable and have incurred losses in each year since our inception. For the three and nine months ended September 30, 2023, we had a net loss of $141.2 million and $268.3 million, respectively. As of September 30, 2023, we had an accumulated deficit of $2.0 billion. Although we began generating revenue from the sale of our Products and Services during the three months ended September 30, 2020, we expect to continue to incur GAAP operating losses for the foreseeable future. As of September 30, 2023, we had a working capital surplus of $306.4 million and capital resources of $300.2 million, consisting of cash, cash equivalents, and short-term investments. In recent years, we have funded our operations primarily through the sale of common stock, convertible senior notes, sales of Products, proceeds from notes issued pursuant to the Note Purchase Agreement, and payments received from collaboration arrangements. We also have a remaining capacity to sell up to $47.2 million of our common stock under the 2022 ATM Agreement as of September 30, 2023. We believe that our existing capital resources will be sufficient to fund the operating plan through at least the next 12 months following the issuance of the unaudited condensed consolidated financial statements in this Report. Basis of Presentation and Principles of Consolidation The accompanying condensed consolidated financial statements are unaudited, and reflect all adjustments which are, in the opinion of management, of a normal recurring nature and necessary for a fair statement of the results for the interim periods presented. Our condensed consolidated balance sheet for the year ended December 31, 2022 included herein was derived from audited consolidated financial statements, but does not include all disclosures including notes required by U.S. GAAP. The interim results presented herein are not necessarily indicative of the results of operations that may be expected for the full fiscal year ending December 31, 2023, or any other future period. Our unaudited condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements contained in our FY2022 10-K. Our condensed consolidated financial statements include our accounts and those of our wholly-owned subsidiaries, and have been prepared in conformity with U.S. GAAP. All intercompany transactions have been eliminated. Reclassification At the beginning of 2023, we changed our presentation of internal-use software where approximately $8.3 million has been reclassified from property and equipment, net into intangible assets, net. Refer to Note 5 for further detail as of September 30, 2023 and December 31, 2022. Use of Estimates & Risks and Uncertainties The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities in the condensed consolidated financial statements and accompanying notes. These estimates form the basis for judgments we make about the carrying values of our assets and liabilities, which are not readily apparent from other sources. We base our estimates and judgments on historical information and on various other assumptions that we believe are reasonable under the circumstances. U.S. GAAP requires us to make estimates and judgments in several areas, including, but not limited to, the incremental borrowing rate used to measure operating lease and finance lease liabilities, the recoverability of goodwill and long-lived assets, useful lives associated with property and equipment and intangible assets, the period of benefit associated with deferred costs, revenue recognition (including the timing of satisfaction of performance obligations, estimating variable consideration, estimating stand-alone selling prices of promised goods and services, and allocation of transaction price to performance obligations), deferred revenue classification, accruals for clinical trial costs, valuation and assumptions underlying stock-based compensation and other equity instruments, and income taxes. As of the date of issuance of these condensed consolidated financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates, judgments or revise the carrying value of our assets or liabilities. These estimates may change as new events occur and additional information is obtained, and are recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to our condensed consolidated financial statements. Significant Accounting Policies There have been no material changes to our significant accounting policies from our FY2022 10-K. Recent Accounting Pronouncements The recent accounting pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and we do not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on our present or future financial statements.

Revenue

Revenue	9 Months Ended
	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenue	Revenue Our revenue is primarily generated from U.S. customers. Our product and collaboration revenues are generated from the Product Segment, and our service revenue is generated from the Service Segment ( Note 13 ). The following table presents our revenue disaggregated by timing of transfer of goods or service: Three Months Ended September 30, 2023 Nine Months Ended September 30, 2023 Transferred Transferred (in thousands) at a point in time over time Total at a point in time over time Total Product revenue $ 54,109 $ — $ 54,109 $ 154,160 $ — $ 154,160 Service revenue — 2,664 2,664 59 9,883 9,942 Collaboration revenue — 3 3 — 139 139 Total revenue $ 54,109 $ 2,667 $ 56,776 $ 154,219 $ 10,022 $ 164,241 Three Months Ended September 30, 2022 Nine Months Ended September 30, 2022 Transferred Transferred (in thousands) at a point in time over time Total at a point in time over time Total Product revenue $ 26,081 $ — $ 26,081 $ 72,401 $ — $ 72,401 Service revenue 121 1,843 1,964 360 3,686 4,046 Collaboration revenue — 970 970 — 6,197 6,197 Total revenue $ 26,202 $ 2,813 $ 29,015 $ 72,761 $ 9,883 $ 82,644 Product Revenue Our product revenue breakdown is summarized below: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Product: RHA ® Collection of dermal fillers $ 32,133 $ 26,081 $ 94,180 $ 72,401 DAXXIFY ® 21,976 — 59,980 — Total product revenue $ 54,109 $ 26,081 $ 154,160 $ 72,401 Accounts receivables and contract liabilities from contracts with our product customers are as follows: September 30, December 31, (in thousands) 2023 2022 Accounts receivables: Accounts receivable, net $ 22,661 $ 10,966 Total accounts receivable, net $ 22,661 $ 10,966 Contract liabilities: Deferred revenue, current $ 398 $ 705 Total contract liabilities $ 398 $ 705 Service Revenue We offer customer payment processing and certain value-added services to aesthetic practices through the Fintech Platform. Generally, revenue related to the HintMD Platform payment processing service, which was discontinued in the second quarter of 2023, was recognized at a point in time and revenue related to the OPUL ® payment processing service is recognized over time. For the Fintech Platform, revenue related to the value-added services component is recognized over time. In September 2023, we commenced a plan to exit the Fintech Platform business as discussed in Note 3 . Accounts receivable from contracts with our service customers are as follows: September 30, December 31, (in thousands) 2023 2022 Accounts receivable: Accounts receivable, net $ 53 $ 59 Total accounts receivable, net $ 53 $ 59 Collaboration Revenue Viatris Agreement Agreement Terms We entered into the Viatris Agreement in February 2018, pursuant to which we are collaborating with Viatris exclusively in the Viatris Territory, to develop, manufacture, and commercialize an onabotulinumtoxinA biosimilar. Viatris has paid us an aggregate of $60 million in non-refundable upfront and milestone fees as of September 30, 2023, and the agreement provides for additional remaining contingent payments of up to $70 million in the aggregate, upon the achievement of certain clinical and regulatory milestones and of specified, tiered sales milestones of up to $225 million. The payments do not represent a financing component for the transfer of goods or services. In addition, Viatris is required to pay us low to mid-double digit royalties on any sales of the biosimilar in the U.S., mid-double digit royalties on any sales in Europe, and high single digit royalties on any sales in other ex-U.S. Viatris territories. However, we have agreed to waive royalties for U.S. sales, up to a maximum of $50 million in annual sales, during the first approximately four years after commercialization to defray launch costs. Revenue Recognition We estimated the transaction price for the Viatris Agreement using the most likely amount method within the scope of ASC 606. In order to determine the transaction price, we evaluated all of the payments to be received during the duration of the contract, which included milestones and consideration payable by Viatris. Other than the upfront payment, all other milestones and consideration we may earn under the Viatris Agreement are subject to uncertainties related to development achievements, Viatris’ rights to terminate the agreement, and estimated effort for cost-sharing payments. Components of such estimated effort for cost-sharing payments include both internal and external costs. Consequently, the transaction price does not include any milestones and considerations that, if included, could result in a probable significant reversal of revenue when related uncertainties become resolved. At the end of each reporting period, we re-evaluate the probability of achievement of each such milestone and any related constraint, and if necessary, adjust our estimates of the overall transaction price. Sales-based milestones and royalties are not included in the transaction price until the sales occur because the underlying value relates to the license, and the license is the predominant feature in the Viatris Agreement. As of September 30, 2023, the transaction price allocated to the unfulfilled performance obligations was $44.2 million. We recognize revenue and estimate deferred revenue based on the cost of development service incurred over the total estimated cost of development services to be provided for the development period. For revenue recognition purposes, the development period is estimated to be completed in 2026. It is possible that this period will change and is assessed at each reporting date. ASC Topic 606, Revenue from Contracts with Customers (ASC 606) requires that an entity include a constraint on the amount of variable consideration included in the transaction price. Variable consideration is considered “constrained” if there is a potential for significant reversal of cumulative revenue recognized. As part of the constraint evaluation, we considered numerous factors, including a potential shift in certain responsibilities between the two parties which would result in changes to the net cost sharing payments, for which outcomes are difficult to predict as of the date of this Report. As a result, no collaboration revenue is recognized from the biosimilar program for the nine months ended September 30, 2023. We will continue to evaluate the variable transaction price and related revenue recognition in each reporting period and as the above uncertainties are resolved or other changes in circumstances occur. For the three and nine months ended September 30, 2023, we recognized no revenue related to development services under the Viatris Agreement. For the three and nine months ended September 30, 2022, we recognized $1.0 million and $6.2 million related to the development services under the Viatris Agreement, respectively. Fosun License Agreement Agreement Terms In December 2018, we entered into the Fosun License Agreement with Fosun, whereby we granted Fosun the exclusive rights to develop and commercialize DaxibotulinumtoxinA for Injection in the Fosun Territory and certain sublicense rights. As of September 30, 2023, Fosun has paid us non-refundable upfront and other payments totaling $38.0 million before foreign withholding taxes. We are also eligible to receive (i) additional remaining contingent payments of up to $222.5 million upon the achievement of certain milestones and (ii) tiered royalty payments in low double digits to high teen percentages on annual net sales. The royalty percentages are subject to reduction in the event that (i) we do not have any valid and unexpired patent claims that cover the product in the Fosun Territory, (ii) biosimilars of the product are sold in the Fosun Territory or (iii) Fosun needs to pay compensation to third parties to either avoid patent infringement or market the product in the Fosun Territory. Revenue Recognition We estimated the transaction price for the Fosun License Agreement using the most likely amount method. We evaluated all of the variable payments to be received during the duration of the contract, which included payments from specified milestones, royalties, and estimated supplies to be delivered. We will re-evaluate the transaction price at each reporting period and upon a change in circumstances. As of September 30, 2023, the transaction price allocated to unfulfilled performance obligation is $41.0 million. For the three and nine months ended September 30, 2023, revenue of less than $0.1 million and $0.1 million was recognized from the Fosun License Agreement, respectively. For the three and nine months ended September 30, 2022, no revenue was recognized from the Fosun License Agreement. Accounts receivables and contract liabilities from contracts with our collaboration customers are as follows: September 30, December 31, (in thousands) 2023 2022 Accounts receivables: Accounts receivable, net — Fosun $ 2,700 $ 315 Total accounts receivable, net $ 2,700 $ 315 Contract liabilities: Deferred revenue, current — Viatris $ 4,973 $ 6,162 Total contract liabilities, current $ 4,973 $ 6,162 Deferred revenue, non-current — Viatris $ 43,340 $ 40,600 Deferred revenue, non-current — Fosun 40,975 37,977 Total contract liabilities, non-current $ 84,315 $ 78,577 Changes in our contract liabilities from contracts with our collaboration revenue customers for the nine months ended September 30, 2023 are as follows: (in thousands) Balance on December 31, 2022 $ 84,739 Revenue recognized (139) Billings and adjustments, net 4,688 Balance on September 30, 2023 $ 89,288

Restructuring

Restructuring	9 Months Ended
	Sep. 30, 2023
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring In September 2023, we commenced a plan to exit the Fintech Platform business because the significant costs and resources required to support OPUL ® no longer aligned with the Company’s capital allocation priorities. The exit and restructuring activities predominantly include a reduction in OPUL ® personnel headcount, the termination of OPUL ® research and development activities and a reduction of outside services expenses related to OPUL ® . We intend to continue processing payments for current OPUL ® customers through January 31, 2024. All of our restructuring charges in connection with the exit of the Fintech Platform business are recorded under our Service Segment. As of September 30, 2023, we recorded restructuring charges of $95.2 million as shown in the table below. We expect to incur estimated additional restructuring charges of up to $3 million, and such restructuring charges will be incurred over time through March 31, 2024. A summary of our restructuring charges included within our condensed consolidated statement of operations for the three and nine months ended September 30, 2023 were as follows: (in thousands) Goodwill impairment $ 77,175 Intangible asset impairment 16,007 Selling, general and administrative 732 Research and development 1,293 Total restructuring charges $ 95,207 A summary of severance and personnel liabilities, included within accruals and other current liabilities on the condensed consolidated balance sheet, is as follows: (in thousands) Balance on December 31, 2022 $ — Severance and other personnel costs 1,432 Cash payment during the period — Balance on September 30, 2023 (1) $ 1,432

Cash Equivalents and Short-Term

Cash Equivalents and Short-Term Investments	9 Months Ended
	Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Cash Equivalents and Short-Term Investments	Cash Equivalents and Short-Term Investments The following table summarizes our cash equivalents and short-term investments: September 30, 2023 December 31, 2022 (in thousands) Adjusted Cost Gain Loss Fair Value Adjusted Cost Losses Fair Value U.S. treasury securities $ 197,446 $ 4 $ — $ 197,450 $ 109,984 $ (228) $ 109,756 Commercial paper 55,162 — (17) 55,145 80,946 — 80,946 Money market funds 29,416 — — 29,416 85,206 — 85,206 Corporate bonds — — — — 41,186 (146) 41,040 U.S. government agency obligations — — — — 4,480 — 4,480 Total cash equivalents and short-term investments $ 282,024 $ 4 $ (17) $ 282,011 $ 321,802 $ (374) $ 321,428 Classified as: Cash equivalents $ 161,085 $ 89,686 Short-term investments 120,926 231,742 Total cash equivalents and short-term investments $ 282,011 $ 321,428 As of September 30, 2023 and December 31, 2022, all of our cash equivalents and short-term investments were available-for-sale securities and had contractual maturities of less than one-year. There were no other-than-temporary impairments on such securities.

Goodwill and intangible Assets,

Goodwill and intangible Assets, net	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and intangible Assets, net	Goodwill and intangible Assets, net Goodwill Goodwill is not amortized but is tested for impairment at least annually at the reporting unit level in the fourth quarter of each calendar year, or more frequently if events or changes in circumstances indicate that the reporting unit might be impaired. In assessing goodwill for impairment, we first assess qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. All of our goodwill was acquired in 2020 as part of the HintMD Acquisition and was assigned to the Service Segment. Based on our plan to exit the Fintech Platform business ( Note 3 ), we concluded that it was more likely than not that goodwill is impaired. Due to our decision to exit the Fintech Platform business, our projected negative future cash flows from the Service Segment resulted in an estimated fair value of zero and full impairment of the related goodwill. We therefor recognized an impairment charge of $77.2 million in our Service Segment for the three and nine months ended September 30, 2023 and was presented as goodwill impairment on the condensed consolidated statement of operations and comprehensive loss. The aggregate amount of accumulated impairment as of September 30, 2023 and December 31, 2022 was $147.0 million and $69.8 million, respectively. The changes in the carrying amount of goodwill by reporting unit during the nine months ended September 30, 2023 was as follows: (in thousands) Product Service Total Balance at December 31, 2022 $ — $ 77,175 $ 77,175 Impairment — (77,175) (77,175) Balance at September 30, 2023 $ — $ — $ — Intangible Assets, net The following table sets forth the major categories of intangible assets and the weighted-average remaining useful lives for those assets that are not already fully amortized: September 30, 2023 (in thousands, except for in years) Weighted Average Remaining Useful Lives Gross Carrying Amount Accumulated Amortization Accumulated Impairment Net Carrying Amount Distribution rights 4.5 $ 32,334 $ (22,518) $ — $ 9,816 Internally developed technology 1.7 8,918 (4,293) (3,972) 653 Other software 0.3 879 (841) — 38 Acquired developed technology 0.0 16,200 (6,525) (9,675) — Customer relationships 0.0 10,300 (7,940) (2,360) — Total intangible assets $ 68,631 $ (42,117) $ (16,007) $ 10,507 December 31, 2022 (in thousands, except for in years) Weighted Average Remaining Useful Lives Gross Carrying Amount Accumulated Amortization Net Carrying Amount Acquired developed technology 4.2 $ 35,800 $ (24,325) $ 11,475 Distribution rights 1.4 32,334 (20,882) 11,452 Internally developed technology 2.4 8,062 (2,271) 5,791 Customer relationships 1.6 10,300 (6,223) 4,077 Other software 1.8 3,166 (1,592) 1,574 Development in progress N/A 975 — 975 Total intangible assets $ 90,637 $ (55,293) $ 35,344 N/A - Not applicable Intangible Asset Impairment As discussed in Note 3 , in September 2023, we commenced a plan to exit the Fintech Platform business and as a result, we concluded that it was more likely than not that the estimated fair value of the asset group for OPUL ® was impaired. We estimated that the fair value of the asset group was effectively zero and recorded a full impairment charge to those intangible assets of $16.0 million for the three and nine months ended September 30, 2023, which was presented as intangible asset impairment on the condensed consolidated statement of operations and comprehensive loss. Intangible Assets Amortization Amortization expense of the intangible assets in the table above were recorded on the condensed consolidated statements of operations and comprehensive loss based on the function of the associated asset. The detail breakdown of the amortization expenses on the condensed consolidated statements of operations and comprehensive loss were summarized as below: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Depreciation and amortization $ 1,320 $ 3,513 $ 5,459 $ 10,538 Selling, general and administrative 429 644 2,998 1,931 Total intangible asset amortization $ 1,749 $ 4,157 $ 8,457 $ 12,469 Based on the amount of intangible assets as of September 30, 2023, the expected amortization expense for each of the next five fiscal years was as follows: Year Ending December 31, (in thousands) 2023 remaining three months $ 700 2024 2,567 2025 2,333 2026 2,181 2027 2,181 2028 and thereafter 545 Total $ 10,507

Inventories

Inventories	9 Months Ended
	Sep. 30, 2023
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consist of the following: September 30, December 31, (in thousands) 2023 2022 Raw materials $ 2,894 $ 505 Work in process 13,490 4,933 Finished goods 29,830 12,887 Total inventories $ 46,214 $ 18,325

Accruals and other current liab

Accruals and other current liabilities	9 Months Ended
	Sep. 30, 2023
Payables and Accruals [Abstract]
Accruals and other current liabilities	Accruals and other current liabilities Accruals and other current liabilities consists of the following: September 30, December 31, (in thousands) 2023 2022 Accruals related to: Compensation (1) $ 26,027 $ 28,014 Inventories 8,376 2,312 Selling, general and administrative 7,711 9,681 Research and development 5,047 9,012 Clinical trials 872 1,863 Interest expense 625 1,912 Other current liabilities 4,835 6,563 Total accruals and other current liabilities $ 53,493 $ 59,357 (1) Restructuring related severance and personnel liabilities included within accruals and other current liabilities on the condensed consolidated balance sheets were discussed in Note 3 .

Leases

Leases	9 Months Ended
	Sep. 30, 2023
Leases [Abstract]
Leases	Leases Operating Leases Our operating leases primarily consist of non-cancellable facilities leases for research, manufacturing, and administrative functions. Our non-cancellable facilities operating leases have original lease periods expiring between 2027 and 2034, and include one or more options to renew for seven years to fourteen years. The monthly payments for our operating leases escalate over the remaining lease term. Our lease contracts do not contain termination options, residual value guarantees or restrictive covenants. Finance Lease Our finance lease represents a dedicated fill-and-finish line for the manufacturing of DAXXIFY ® . In March 2017, we entered into the ABPS Services Agreement. The ABPS Services Agreement contains a lease, which commenced in January 2022, related to a dedicated fill-and-finish line for the manufacturing of DAXXIFY ® because it has an identified asset that is physically distinct for which we have the right of control as defined under ASC 842. The right of control is conveyed because the embedded lease provides us with both (i) the right to obtain substantially all of the economic benefit from the fill-and-finish line resulting from the exclusivity of the dedicated manufacturing capacity and (ii) the right to direct the use of the fill-and-finish line through our purchase orders to ABPS. Each party has the right to terminate the ABPS Services Agreement without cause, with an 18-month written notice to the other party. The lease is classified as a finance lease in the condensed consolidated balance sheets. Under the ABPS Services Agreement, until May 2022, we were subject to minimum purchase obligations of up to $30.0 million for each of the years ending December 31, 2022, 2023 and 2024. In May 2022, we amended a statement of work under the ABPS Services Agreement pursuant to which the minimum purchase obligations of $30.0 million per year were eliminated, and instead the minimum purchase obligations would be negotiated prior to the beginning of each year over the term of the agreement. As a result of the amended statement of work, the finance lease was modified. The primary change was that the modification reflects payments in 2023 and 2024 as variable lease payments, contingent on negotiation at the beginning of each period and excludes such payments in the present value calculation in arriving at the remaining finance lease liabilities with a corresponding adjustment to the related right-of-use asset, among other considerations and changes. In January 2023, we entered into a second amendment to the above mentioned statement of work under the ABPS Services Agreement. The second amendment established a minimum purchase obligation for the year ending December 31, 2023 of $23.9 million, which represents ABPS’ practical manufacturing capability based on experience. The minimum purchase obligation for the year ending December 31, 2023 was determined to be fixed lease payments and such payments will increase the present value calculation in arriving at the remaining finance lease liabilities with a corresponding adjustment to the related finance lease right-of-use asset. The operating and finance lease costs are summarized as follows: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Finance lease: Amortization of finance lease right-of-use asset (1) $ 3,297 $ 3,344 $ 6,965 $ 4,502 Interest on finance lease liability 270 348 1,278 2,607 Variable lease cost (2) 62 1,134 436 1,375 Total finance lease costs 3,629 4,826 8,679 8,484 Operating leases: Operating lease cost 3,138 2,223 9,657 6,669 Variable lease cost (3) 534 423 1,589 1,288 Total operating lease costs 3,672 2,646 11,246 7,957 Total lease costs $ 7,301 $ 7,472 $ 19,925 $ 16,441 (1) Amortization of the finance lease right-of-use asset started to be capitalized into inventories on the condensed consolidated balance sheets in the second quarter of 2023 as a result of the FDA approval of the PAS of the ABPS manufacturing facility. (2) Variable finance lease cost includes validation, qualification, materials, and other related services which are not included in the lease liabilities and are expensed as incurred. (3) Variable operating lease cost includes management fees, common area maintenance, property taxes, insurance and parking fees, which are not included in the lease liabilities and are expensed as incurred. As of September 30, 2023, maturities of our lease liabilities are as follows: (in thousands) Finance Lease Operating Leases Total Year Ending December 31, 2023 remaining three months $ 5,647 $ 5,065 $ 10,712 2024 3,102 10,491 13,593 2025 — 10,854 10,854 2026 — 11,185 11,185 2027 — 4,536 4,536 2028 and thereafter — 28,586 28,586 Total lease payments 8,749 70,717 79,466 Less imputed interest (139) (19,779) (19,918) Present value of lease payments $ 8,610 $ 50,938 $ 59,548 Our lease contracts do not provide readily determinable implicit rates, as such, we used the estimated incremental borrowing rate based on the information available at the adoption, commencement, or remeasurement date. As of September 30, 2023, weighted-average remaining lease terms and discount rates are as follows: Finance Leases Operating Leases Weighted-average remaining lease term (years) 2.5 8.4 Weighted-average discount rate 10.7 % 10.0 % Supplemental cash flow information related to the leases was as follows: Nine Months Ended September 30, (in thousands) 2023 2022 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 6,264 $ 6,259 Operating cash flows from finance lease $ 1,280 $ 2,541 Financing cash flows from finance lease $ 15,513 $ 5,000 Right-of-use assets obtained in exchange for lease liabilities Finance lease $ 23,781 $ 14,523 Operating leases (1) $ 22,694 $ — (1) In September 2023, the Expansion Premises and Second Expansion Premises commenced resulting in recognition of $22.7 million right-of-use asset and $16.2 million lease liability. Lease Not Yet Commenced PCI Supply Agreement In April 2021, we entered into the PCI Supply Agreement pursuant to which PCI would serve as a non-exclusive manufacturer and supplier of DAXXIFY ® . The initial term of the PCI Supply Agreement is dependent upon the date of regulatory submission for the manufacturing of DAXXIFY ® and may be terminated by either party in accordance with the terms of the PCI Supply Agreement. The term of the PCI Supply Agreement may also be extended for one additional three-year term upon mutual agreement of the parties. The PCI Supply Agreement contains a lease related to a dedicated fill-and-finish line and closely related assets for the manufacturing of DAXXIFY ® because it has identified assets that are physically distinct for which we will have the right of control as defined under ASC 842. The right of control is conveyed because the embedded lease will provide us with both (i) the right to obtain substantially all of the economic benefit from the fill-and-finish line resulting from the exclusivity implied from the dedicated manufacturing capacity and (ii) the right to direct the use of the fill-and-finish line. The embedded lease had not yet commenced as of September 30, 2023. The accounting commencement and recognition of the right-of-use lease assets and lease liabilities related to the embedded lease will take place when we have substantively obtained the right of control. The embedded lease is preliminarily classified as a finance lease. Pursuant to the PCI Supply Agreement, we are responsible for certain costs associated with the design, equipment procurement and validation, and facilities-related costs, monthly payments and minimum purchase obligations throughout the initial term of the PCI Supply Agreement. As of September 30, 2023, we have made prepayments of $30.9 million to PCI which is recorded within “Finance lease prepaid expense” in the condensed consolidated balance sheets. Based on our best estimate as of September 30, 2023, our remaining minimum commitment under the PCI Supply Agreement will be $10.9 million for 2023, $15.9 million for 2024, $18.3 million for 2025, $25.3 million for 2026, $29.5 million for 2027, and $134.5 million for 2028 and thereafter in the aggregate.
Leases	Leases Operating Leases Our operating leases primarily consist of non-cancellable facilities leases for research, manufacturing, and administrative functions. Our non-cancellable facilities operating leases have original lease periods expiring between 2027 and 2034, and include one or more options to renew for seven years to fourteen years. The monthly payments for our operating leases escalate over the remaining lease term. Our lease contracts do not contain termination options, residual value guarantees or restrictive covenants. Finance Lease Our finance lease represents a dedicated fill-and-finish line for the manufacturing of DAXXIFY ® . In March 2017, we entered into the ABPS Services Agreement. The ABPS Services Agreement contains a lease, which commenced in January 2022, related to a dedicated fill-and-finish line for the manufacturing of DAXXIFY ® because it has an identified asset that is physically distinct for which we have the right of control as defined under ASC 842. The right of control is conveyed because the embedded lease provides us with both (i) the right to obtain substantially all of the economic benefit from the fill-and-finish line resulting from the exclusivity of the dedicated manufacturing capacity and (ii) the right to direct the use of the fill-and-finish line through our purchase orders to ABPS. Each party has the right to terminate the ABPS Services Agreement without cause, with an 18-month written notice to the other party. The lease is classified as a finance lease in the condensed consolidated balance sheets. Under the ABPS Services Agreement, until May 2022, we were subject to minimum purchase obligations of up to $30.0 million for each of the years ending December 31, 2022, 2023 and 2024. In May 2022, we amended a statement of work under the ABPS Services Agreement pursuant to which the minimum purchase obligations of $30.0 million per year were eliminated, and instead the minimum purchase obligations would be negotiated prior to the beginning of each year over the term of the agreement. As a result of the amended statement of work, the finance lease was modified. The primary change was that the modification reflects payments in 2023 and 2024 as variable lease payments, contingent on negotiation at the beginning of each period and excludes such payments in the present value calculation in arriving at the remaining finance lease liabilities with a corresponding adjustment to the related right-of-use asset, among other considerations and changes. In January 2023, we entered into a second amendment to the above mentioned statement of work under the ABPS Services Agreement. The second amendment established a minimum purchase obligation for the year ending December 31, 2023 of $23.9 million, which represents ABPS’ practical manufacturing capability based on experience. The minimum purchase obligation for the year ending December 31, 2023 was determined to be fixed lease payments and such payments will increase the present value calculation in arriving at the remaining finance lease liabilities with a corresponding adjustment to the related finance lease right-of-use asset. The operating and finance lease costs are summarized as follows: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Finance lease: Amortization of finance lease right-of-use asset (1) $ 3,297 $ 3,344 $ 6,965 $ 4,502 Interest on finance lease liability 270 348 1,278 2,607 Variable lease cost (2) 62 1,134 436 1,375 Total finance lease costs 3,629 4,826 8,679 8,484 Operating leases: Operating lease cost 3,138 2,223 9,657 6,669 Variable lease cost (3) 534 423 1,589 1,288 Total operating lease costs 3,672 2,646 11,246 7,957 Total lease costs $ 7,301 $ 7,472 $ 19,925 $ 16,441 (1) Amortization of the finance lease right-of-use asset started to be capitalized into inventories on the condensed consolidated balance sheets in the second quarter of 2023 as a result of the FDA approval of the PAS of the ABPS manufacturing facility. (2) Variable finance lease cost includes validation, qualification, materials, and other related services which are not included in the lease liabilities and are expensed as incurred. (3) Variable operating lease cost includes management fees, common area maintenance, property taxes, insurance and parking fees, which are not included in the lease liabilities and are expensed as incurred. As of September 30, 2023, maturities of our lease liabilities are as follows: (in thousands) Finance Lease Operating Leases Total Year Ending December 31, 2023 remaining three months $ 5,647 $ 5,065 $ 10,712 2024 3,102 10,491 13,593 2025 — 10,854 10,854 2026 — 11,185 11,185 2027 — 4,536 4,536 2028 and thereafter — 28,586 28,586 Total lease payments 8,749 70,717 79,466 Less imputed interest (139) (19,779) (19,918) Present value of lease payments $ 8,610 $ 50,938 $ 59,548 Our lease contracts do not provide readily determinable implicit rates, as such, we used the estimated incremental borrowing rate based on the information available at the adoption, commencement, or remeasurement date. As of September 30, 2023, weighted-average remaining lease terms and discount rates are as follows: Finance Leases Operating Leases Weighted-average remaining lease term (years) 2.5 8.4 Weighted-average discount rate 10.7 % 10.0 % Supplemental cash flow information related to the leases was as follows: Nine Months Ended September 30, (in thousands) 2023 2022 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 6,264 $ 6,259 Operating cash flows from finance lease $ 1,280 $ 2,541 Financing cash flows from finance lease $ 15,513 $ 5,000 Right-of-use assets obtained in exchange for lease liabilities Finance lease $ 23,781 $ 14,523 Operating leases (1) $ 22,694 $ — (1) In September 2023, the Expansion Premises and Second Expansion Premises commenced resulting in recognition of $22.7 million right-of-use asset and $16.2 million lease liability. Lease Not Yet Commenced PCI Supply Agreement In April 2021, we entered into the PCI Supply Agreement pursuant to which PCI would serve as a non-exclusive manufacturer and supplier of DAXXIFY ® . The initial term of the PCI Supply Agreement is dependent upon the date of regulatory submission for the manufacturing of DAXXIFY ® and may be terminated by either party in accordance with the terms of the PCI Supply Agreement. The term of the PCI Supply Agreement may also be extended for one additional three-year term upon mutual agreement of the parties. The PCI Supply Agreement contains a lease related to a dedicated fill-and-finish line and closely related assets for the manufacturing of DAXXIFY ® because it has identified assets that are physically distinct for which we will have the right of control as defined under ASC 842. The right of control is conveyed because the embedded lease will provide us with both (i) the right to obtain substantially all of the economic benefit from the fill-and-finish line resulting from the exclusivity implied from the dedicated manufacturing capacity and (ii) the right to direct the use of the fill-and-finish line. The embedded lease had not yet commenced as of September 30, 2023. The accounting commencement and recognition of the right-of-use lease assets and lease liabilities related to the embedded lease will take place when we have substantively obtained the right of control. The embedded lease is preliminarily classified as a finance lease. Pursuant to the PCI Supply Agreement, we are responsible for certain costs associated with the design, equipment procurement and validation, and facilities-related costs, monthly payments and minimum purchase obligations throughout the initial term of the PCI Supply Agreement. As of September 30, 2023, we have made prepayments of $30.9 million to PCI which is recorded within “Finance lease prepaid expense” in the condensed consolidated balance sheets. Based on our best estimate as of September 30, 2023, our remaining minimum commitment under the PCI Supply Agreement will be $10.9 million for 2023, $15.9 million for 2024, $18.3 million for 2025, $25.3 million for 2026, $29.5 million for 2027, and $134.5 million for 2028 and thereafter in the aggregate.

Debt

Debt	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Debt	Debt The following table provides information regarding our debt: September 30, December 31, (in thousands) 2023 2022 2027 Notes, non-current $ 287,500 $ 287,500 Less: Unamortized debt issuance costs (4,609) (5,587) Carrying amount of the 2027 Notes 282,891 281,913 Notes Payable, current 1,250 — Notes Payable, non-current 148,750 100,000 Less: Unamortized debt discount (2,976) (1,347) Less: Unamortized debt issuance costs (1,564) (1,192) Carrying amount of Notes Payable 145,460 97,461 Total debt $ 428,351 $ 379,374 Interest expense relating to our debt in the condensed consolidated statements of operations and comprehensive loss are summarized as follows: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Contractual interest expense $ 3,830 $ 3,454 $ 10,620 $ 8,425 Amortization of debt issuance costs 447 441 1,310 1,190 Amortization of debt discount 157 98 329 183 Total interest expense $ 4,434 $ 3,993 $ 12,259 $ 9,798 Convertible Senior Notes In February 2020, we issued the 2027 Notes, in the aggregate principal amount of $287.5 million pursuant to the Indenture. The 2027 Notes are senior unsecured obligations and bear interest at a rate of 1.75% per year, payable semiannually in arrears on February 15 and August 15 of each year, began on August 15, 2020. The 2027 Notes will mature on February 15, 2027, unless earlier converted, redeemed or repurchased. In connection with issuing the 2027 Notes, we received $278.3 million in net proceeds, after deducting the initial purchasers’ discount, commissions, and other issuance costs. The 2027 Notes may be converted at any time by the holders prior to the close of business on the business day immediately preceding November 15, 2026 only under the following circumstances: (i) during any fiscal quarter commencing after the fiscal quarter ending on June 30, 2020 (and only during such fiscal quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (ii) during the five business day period after any ten consecutive trading day period (the “measurement period”) in which the trading price (as defined in the Indenture) per $1,000 principal amount of the 2027 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; (iii) if we call any or all of the 2027 Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (iv) upon the occurrence of specified corporate events. On or after November 15, 2026 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their 2027 Notes at any time, regardless of the foregoing circumstances. Upon conversion, we will pay or deliver, as the case may be, cash, shares of our common stock or a combination of cash and shares of our common stock, at our election. The conversion rate will initially be 30.8804 shares of our common stock per $1,000 principal amount of the 2027 Notes (equivalent to an initial conversion price of approximately $32.38 per share of our common stock). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date or if we deliver a notice of redemption, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert its 2027 Notes in connection with such a corporate event or notice of redemption, as the case may be. Contractually, we may not redeem the 2027 Notes prior to February 20, 2024. We may redeem for cash all or any portion of the 2027 Notes, at our option, on or after February 20, 2024 if the last reported sale price of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to 100% of the principal amount of the 2027 Notes to be redeemed, plus any accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the 2027 Notes. If we undergo a fundamental change (as defined in the Indenture), holders may require us to repurchase for cash all or any portion of their 2027 Notes at a fundamental change repurchase price equal to 100% of the principal amount of the 2027 Notes to be repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. Capped Call Transactions Concurrently with the 2027 Notes, we entered into capped call transactions with the option counterparties and used $28.9 million of the net proceeds from the 2027 Notes to pay the cost of the capped call transactions. The capped call transactions are expected generally to reduce the potential dilutive effect upon conversion of the 2027 Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted 2027 Notes, as the case may be, with such reduction and/or offset subject to a price cap of $48.88 of our common stock per share, which represents a premium of 100% over the last reported sale price of our common stock on February 10, 2020. The cap ped calls have an initial strike price of $32.38 per share, subject to certain adjustments, which corresponds to the conversion option strike price in the 2027 Notes. The capped call transactions cover, subject to anti-dilution adjustments, approximately 8.9 million shares of our common stock. The capped call transactions are separate transactions that we entered into with the option counterparties and are not part of the terms of the 2027 Notes. As the capped call transactions meet certain accounting criteria, the premium paid of $28.9 million was recorded as a reduction in additional paid-in capital in the condensed consolidated balance sheets, and will not be remeasured to fair value as long as the accounting criteria continue to be met. As of September 30, 2023 and December 31, 2022, we had not purchased any shares under the capped call transactions. Note Purchase Agreement In March 2022, we entered into the Note Purchase Agreement and issued the First Tranche in an aggregate principal amount for all such Notes of $100 million. In August 2023, we entered into the First Amendment to reduce the Second Tranche from $100 million to $50 million, and we subsequently issued $50 million to the purchasers. Additionally, the First Amendment increased the uncommitted Third Tranche from $100 million to $150 million. The uncommitted Third Tranche is available until March 31, 2024, subject to the satisfaction of certain conditions set forth in the Note Purchase Agreement, including the achievement of greater than or equal to $50 million in trailing twelve months revenue for DAXXIFY ® preceding the date of the draw request for the Third Tranche, and approval by Athyrium. Our obligations under the Note Purchase Agreement are secured by substantially all of our assets and the assets of our wholly owned domestic subsidiaries, including their respective intellectual property. The notes issued pursuant to the First Tranche and Second Tranche bear interest at an annual fixed interest rate equal to 8.50%. The First Amendment modified the variable interest rate adjustment for the Third Tranche from Adjusted Three-Month LIBOR to Adjusted Three-Month Term SOFR. If the Third Tranche of Notes Payable becomes committed, the Notes Payable will then bear interest at an annual rate equal to the sum of (a) 7.0% and (b) Adjusted Three-Month Term SOFR for such interest period (subject to a floor of 1.50% and a cap of 2.50%). We are required to make quarterly interest payments on each Notes Payable commencing on the last business day of the calendar month following the funding date thereof, and continuing until the Maturity Date. Pursuant to the First Amendment, the Company is required to repay Athyrium the outstanding principal amount of the Second Tranche notes in installments on the last business day of each March, June, September and December (commencing in September 2024), in each case, based on the following principal amortization payment schedule: 2.5% in September and December 2024; 5.0% in March and June 2025; 7.5% in September and December 2025; and 10.0% in March and June 2026; followed by repayment of the Second Tranche in full on September 18, 2026. The Maturity Date may be extended to March 18, 2028 if, as of September 18, 2026, less than $90 million principal amount of our existing 2027 Notes remain outstanding and with the consent of the Purchasers. Initially, all principal for each tranche is due and payable on the Maturity Date. If any Third Tranche notes are issued, upon the occurrence of an Amortization Trigger (as defined in the Note Purchase Agreement), we are required to repay the principal of the Third Tranche in equal monthly installments beginning on the last day of the month in which the Amortization Trigger occurred and continuing through the Maturity Date. At our option, we may prepay the outstanding principal balance of all or any portion of the principal amount of the Notes Payable, subject to a prepayment fee equal to (i) a make-whole amount if the prepayment occurs on or prior to the first anniversary of the NPA Effective Date and (ii) 2.0% of the amount prepaid if the prepayment occurs after the first anniversary of the NPA Effective Date but on or prior to the second anniversary of the NPA Effective Date. Upon prepayment or repayment of all or any portion of the principal amount of the Notes Payable (whether on the Maturity Date or otherwise), we are also required to pay an exit fee to the Purchasers. The Note Purchase Agreement includes affirmative and negative covenants applicable to us, our current subsidiaries and any subsidiaries we create in the future. The affirmative covenants include, among others, covenants requiring us to maintain our legal existence and governmental approvals, deliver certain financial reports, maintain insurance coverage and satisfy certain requirements regarding deposit accounts. We must also (i) maintain at least $30.0 million of unrestricted cash and cash equivalents in accounts subject to a control agreement in favor of Athyrium at all times and (ii) upon the occurrence of certain specified events set forth in the Note Purchase Agreement, achieve at least $70.0 million of Consolidated Teoxane Distribution Net Product Sales on a trailing twelve-months basis. The negative covenants include, among others, restrictions on our transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens, selling assets and undergoing a change in control, in each case subject to certain exceptions. If we do not comply with the affirmative and negative covenants, such non-compliance may be an event of default under the Note Purchase Agreement. The Note Purchase Agreement also includes events of default, the occurrence and continuation of which could cause interest to be charged at the rate that is otherwise applicable plus 2.0% and would provide Athyrium, as administrative agent, with the right to exercise remedies against us and the collateral, including foreclosure against our property securing the obligations under the Note Purchase Agreement, including our cash. These events of default include, among other things, our failure to pay principal or interest due under the Note Purchase Agreement, a breach of

Stockholders_ Equity and Stock-

Stockholders’ Equity and Stock-Based Compensation	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Stockholders’ Equity and Stock-Based Compensation	Stockholders’ Equity and Stock-Based Compensation Equity Compensation Plans 2014 EIP On January 1, 2023, the number of shares of common stock reserved for issuance under the 2014 EIP increased by 3.3 million shares. For the nine months ended September 30, 2023, 2.5 million shares of stock awards and 0.2 million stock options were granted under the 2014 EIP. As of September 30, 2023, 4.3 million shares were available for issuance under the 2014 EIP. 2014 IN For the nine months ended September 30, 2023, no stock options or awards were granted under the 2014 IN. As of September 30, 2023, 1.1 million shares were available for issuance under the 2014 IN. HintMD Plan For the nine months ended September 30, 2023, no stock options or awards were granted under the HintMD Plan. As of September 30, 2023, 0.1 million shares were available for issuance under the HintMD Plan. 2014 ESPP On January 1, 2023, the number of shares of common stock reserved for issuance under the 2014 ESPP increased by 0.3 million shares. As of September 30, 2023, 1.8 million shares were available for issuance under the 2014 ESPP. Net Loss per Share Our basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is calculated by giving effect to all potential dilutive common stock equivalents outstanding for the period. For purposes of this calculation, shares of common stock underlying the 2027 Notes at the initial conversion price, outstanding stock options, and unvested stock awards, are considered common stock equivalents, which were excluded from the computation of diluted net loss per share because including them would have been antidilutive. Common stock equivalents that were excluded from the computation of diluted net loss per share are presented below: September 30, 2023 2022 Convertible senior notes 8,878,938 8,878,938 Outstanding stock options 3,886,868 4,957,025 Unvested RSUs and PSUs 3,266,886 2,690,816 Unvested RSAs and PSAs 949,059 2,339,999 Shares of common stock expected to be purchased on December 31st under the 2014 ESPP 118,258 188,715 ATM Offering Programs In November 2020, we entered into the 2020 ATM Agreement with Cowen. Under the 2020 ATM Agreement, we could offer and sell, from time to time, through Cowen, shares of our common stock having an aggregate offering price of up to $125.0 million. We were not obligated to sell any shares under the 2020 ATM Agreement. Subject to the terms and conditions of the 2020 ATM Agreement, Cowen was required to use commercially reasonable efforts, consistent with its normal trading and sales practices, applicable state and federal law, rules and regulations and the rules of The Nasdaq Global Market, to sell shares from time to time based upon our instructions, including any price, time or size limits specified by us. We paid Cowen a commission of up to 3.0% of the aggregate gross proceeds from each sale of shares, reimbursed legal fees and disbursements and provided Cowen with customary indemnification and contribution rights. From January 1, 2022 through May 10, 2022, we sold 1.7 million shares of common stock under the 2020 ATM Agreement at a weighted average price of $18.71 per share resulting in net proceeds of $31.6 million after sales agent commissions and offering costs. The 2020 ATM Agreement was terminated on May 10, 2022. On May 10, 2022, we entered into the 2022 ATM Agreement with Cowen. Under the 2022 ATM Agreement, we may sell up to $150.0 million of our common stock. We are not obligated to sell any shares under the 2022 ATM Agreement. Subject to the terms and conditions of the 2022 ATM Agreement, Cowen will use commercially reasonable efforts, consistent with its normal trading and sales practices, applicable state and federal law, rules and regulations and the rules of The Nasdaq Global Market, to sell shares from time to time based upon our instructions, including any price, time or size limits specified by us. We pay Cowen a commission of up to 3.0% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Cowen with customary indemnification and contribution rights. In the three months ended June 30, 2023, we sold 3.2 million shares of common stock under the 2022 ATM Agreement at a weighted average price of $31.90 per share, resulting in net proceeds of $100.0 million after sales agent commissions and offering costs. No shares of common stock were sold for the three months ended March 31, 2023 or September 30, 2023 under the 2022 ATM Agreement. Stock-Based Compensation Expense The following table summarizes our stock-based compensation expense by line item in our condensed consolidated statements of operations and comprehensive loss: (in thousands) Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Selling, general and administrative $ 8,599 $ 13,245 $ 31,042 $ 27,937 Research and development 1,688 4,742 7,926 13,676 Cost of product revenue (exclusive of depreciation and amortization) 358 — 1,306 — Total stock-based compensation expense, net of amounts capitalized 10,645 17,987 40,274 41,613 Capitalized stock-based compensation 1,212 566 2,901 682 Total stock-based compensation expense $ 11,857 $ 18,553 $ 43,175 $ 42,295

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The following table summarizes, for assets and liabilities measured at fair value, the respective fair value and the classification by level of input within the fair value hierarchy. September 30, 2023 (in thousands) Fair Value Level 1 Level 2 Level 3 Assets U.S. treasury securities $ 197,450 $ 197,450 $ — $ — Money market funds 29,416 29,416 — — Commercial paper 55,145 — 55,145 — Total assets measured at fair value $ 282,011 $ 226,866 $ 55,145 $ — December 31, 2022 (in thousands) Fair Value Level 1 Level 2 Level 3 Assets U.S. treasury securities $ 109,756 $ 109,756 $ — $ — Money market funds 85,206 85,206 — — U.S. government agency obligations 4,480 4,480 — — Commercial paper 80,946 — 80,946 — Corporate bonds 41,040 — 41,040 — Total assets measured at fair value $ 321,428 $ 199,442 $ 121,986 $ — For Level 1 investments, we use quoted prices in active markets for identical assets to determine the fair value. For Level 2 investments, we use quoted prices for similar assets sourced from certain third-party pricing services. The third-party pricing services generally utilize industry standard valuation models for which all significant inputs are observable, either directly or indirectly, to estimate the price or fair value of the securities. The primary input generally includes reported trades of or quotes on the same or similar securities. We do not make additional judgments or assumptions made to the pricing data sourced from the third-party pricing services. The fair value of the 2027 Notes and the Notes Payable ( Note 9 ) was determined on the basis of market prices observable for similar instruments and is considered Level 2 in the fair value hierarchy. We present the fair value of the 2027 Notes and the Notes payable for disclosure purposes only. As of September 30, 2023, and December 31, 2022, the fair value of the 2027 Notes was $232.1 million and $288.2 million, respectively. As of September 30, 2023 and December 31, 2022, the fair value of the Notes Payable was approximately the same as its unamortized carrying value.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Teoxane Agreement In January 2020, we entered into the Teoxane Agreement, pursuant to which Teoxane granted us the exclusive right to import, market, promote, sell and distribute Teoxane’s line of Resilient Hyaluronic Acid ® dermal fillers, which include: (i) RHA ® Collection of dermal fillers, and (ii) the RHA ® Pipeline Products in the U.S. and U.S. territories and possessions, in exchange for 2,500,000 shares of our common stock and certain other commitments by us. The Teoxane Agreement is effective for a term of ten years from product launch in September 2020 and may be extended for a two-year period upon the mutual agreement of the parties. We are required to meet certain minimum purchase obligations during each year of the term. Our minimum purchase obligation for the years ending December 31, 2023 and December 31, 2024 will be $40 million and $52 million, respectively. Minimum purchase obligations after December 31, 2024 may be determined at a later date. We are also required to meet certain minimum expenditure requirements in connection with commercialization efforts. Our minimum expenditures related to the commercialization and promotion of RHA ® Collection of dermal fillers and RHA ® Pipeline Products for the years ended December 31, 2023 and 2024 will be $34 million and $36 million, respectively. Minimum expenditures related to the commercialization and promotion of RHA ® Collection of dermal fillers and RHA ® Pipeline Products after December 31, 2024 may be determined at a later date. Either party may terminate the Teoxane Agreement in the event of the insolvency of, or a material breach by, the other party, including certain specified breaches that include the right for Teoxane to terminate the Teoxane Agreement for our failure to meet the minimum purchase requirements or commercialization expenditure during specified periods, or for our breach of the exclusivity obligations under the Teoxane Agreement. Other Contingencies As of September 30, 2023, we are obligated to pay BTRX up to a remaining $15.5 million upon the satisfaction of certain milestones relating to our product revenue, intellectual property, and clinical and regulatory events. Indemnification We have standard indemnification agreements in the ordinary course of business. Under these indemnification agreements, we indemnify, hold harmless, and agree to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to our technology. The term of these indemnification agreements is generally perpetual after the execution of the agreements. The maximum potential amount of future payments we are obligated to pay under other indemnification agreements is not determinable because it involves claims for indemnification that may be made against us in the future but have not been made. We have not yet incurred material costs to defend lawsuits or settle claims related to indemnification agreements. We have indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual. For the nine months ended September 30, 2023 and 2022, no material amounts associated with the indemnification agreements have been recorded. Litigation In October 2021, Allergan filed a complaint against us and ABPS, one of our manufacturing sources of DAXXIFY ® , in the U.S. District Court for the District of Delaware, alleging infringement of the following patents assigned and/or licensed to Allergan: U.S. Patent Nos. 11,033,625; 7,354,740; 8,409,828; 11,124,786; and 7,332,567. Allergan claims that our formulation for DAXXIFY ® and ABPS’s manufacturing process used to produce DAXXIFY ® infringes its patents. Allergan also asserted a patent with claims related to a substrate for use in a botulinum toxin detection assay. On November 3, 2021, we filed a motion to dismiss. On November 24, 2021, Allergan filed an amended complaint against us and ABPS, alleging infringement of an additional patent assigned and/or licensed to Allergan: U.S. Patent No. 11,147,878. On December 17, 2021, we filed a second motion to dismiss, and on January 14, 2022, Allergan filed an opposition to that motion. We filed a reply to Allergan’s opposition on January 21, 2022, and on August 19, 2022, the court denied our second motion to dismiss. On September 2, 2022, we filed an answer and counterclaims to Allergan’s amended complaint. On December 30, 2022, Allergan filed a second amended complaint against us and ABPS, alleging infringement of three additional patents assigned and/or licensed to Allergan: U.S. Patent Nos. 11,203,748; 11,326,155; and 11,285,216. On January 20, 2023, we filed an answer and counterclaims to Allergan's second amended complaint. On March 3, 2023, we filed invalidity contentions, which challenge Allergan’s asserted patents. A Markman hearing was held on June 28, 2023, and a decision was issued on August 29, 2023. On September 15, 2023, U.S. Patent No. 7,332,567 was dismissed from the case with prejudice. On December 10, 2021, a putative securities class action complaint was filed against the Company and certain of its officers on behalf of a class of stockholders who acquired the Company’s securities from November 25, 2019 to October 11, 2021, in the U.S. District Court for the Northern District of California. The complaint alleges that the Company and certain of its officers violated Sections 10(b) and 20(a) of Exchange Act by making false and misleading statements regarding the manufacturing of DAXXIFY ® and the timing and likelihood of regulatory approval and seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys’ fees. The court appointed the lead plaintiff and lead counsel on September 7, 2022. The lead plaintiff filed an amended complaint on November 7, 2022. On January 23, 2023, we filed a motion to dismiss. On March 8, 2023, the lead plaintiff filed an opposition to our motion to dismiss. On April 7, 2023, we filed a reply in support of our motion to dismiss. A hearing on our motion to dismiss took place on August 10, 2023, and we are awaiting a decision from the court. We cannot be certain of whether that motion to dismiss will be granted. We dispute the claims in these lawsuits and intend to defend the matters vigorously. These lawsuits are subject to inherent uncertainties, and the actual defense and disposition costs will depend upon many unknown factors. The outcome of the lawsuits is necessarily uncertain. We could be forced to expend significant resources in the defense of either lawsuit, and we may not prevail. In addition, we may incur substantial legal fees and costs in connection with each lawsuit. We record a provision for a liability when we believe that it is both probable that a liability has incurred, and the amount can be reasonably estimated. As of both September 30, 2023 and December 31, 2022, no such provision for liabilities related to the above litigation matters were recorded on the condensed consolidated balance sheets.

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
Segment Information	Segment Information Reportable Segments We report segment information based on the management approach. The management approach designates the internal reporting used by the CODM for making decisions and assessing performance as the source of our reportable segments. We have two reportable segments: the Product Segment and the Service Segment. Each reportable segment represents a component, or an operating segment, for which separate financial information is available that is utilized on a regular basis by our CODM in determining resource allocations and performance evaluation. We also considered whether the identified operating segments should be further aggregated based on factors including economic characteristics, the nature of products and services, production processes, customer base, distribution methods, and regulatory environment; however, no such aggregation was made due to dissimilarity of the operating segments. Product Segment Our Product Segment refers to the business that includes the research, development and commercialization of our approved products and product candidates, including DAXXIFY ® , the onabotulinumtoxinA biosimilar and the RHA ® Collection of dermal fillers. Service Segment Our Service Segment refers to the business that includes the development and commercialization of the Fintech Platform. In September 2023, we commenced a restructuring plan to exit the Fintech Platform business. We expect all Fintech Platform payment operations to be discontinued by or around March 31, 2024. Corporate and Other Expenses Corporate and other expenses include operating expenses related to general and administrative expenses, depreciation and amortization, stock-based compensation, and intersegment elimination that are not used in evaluating the results of, or in allocating resources to, our segments. Intersegment revenue represents the revenue generated between the two segments. For the three months ended September 30, 2023 and 2022, intersegment revenue was $0.7 million and $0.4 million, respectively. For the nine months ended September 30, 2023 and 2022, intersegment revenue was $2.0 million and $0.9 million, respectively. Reconciliation of Segment Revenue to Consolidated Revenue Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Revenue: Product Segment $ 54,112 $ 27,051 $ 154,299 $ 78,598 Service Segment 2,664 1,964 9,942 4,046 Total revenue $ 56,776 $ 29,015 $ 164,241 $ 82,644 Reconciliation of Segment Loss from Operations to Consolidated Loss from Operations Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Loss from operations: Product Segment $ (9,032) $ (32,100) $ (41,097) $ (82,020) Service Segment (1) (98,169) (4,423) (110,234) (13,956) Corporate and other expenses (32,092) (40,961) (111,493) (101,571) Total loss from operations $ (139,293) $ (77,484) $ (262,824) $ (197,547) (1) For the three and nine months ended September 30, 2023, loss from operations for the Service Segment included an impairment loss of $93.2 million as discussed in Note 5 . We do not evaluate performance or allocate resources based on segment asset data, and therefore such information is not presented.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Pay vs Performance Disclosure
Net loss	$ (141,176)	$ (84,693)	$ (268,287)	$ (210,470)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	9 Months Ended
	Sep. 30, 2023 shares	Sep. 30, 2023 shares
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		The adoption or termination of contracts, instructions or written plans for the purchase or sale of our securities by our Section 16 officers and directors for the three months ended September 30, 2023, each of which is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, were as follows: Name and Title Action Date of Action Total Shares to be Sold Expiration Date Mark Foley, Chief Executive Officer Terminate (1) 8/28/23 442,576 5/31/2024 Olivia Ware, Director Adopt 8/31/23 9,593 8/30/2024 (1) Mr. Foley entered into this 10b5-1 Plan on March 10, 2023
Non-Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Terminated	false
Mark Foley [Member]
Trading Arrangements, by Individual
Name	Mark Foley
Title	Chief Executive Officer
Rule 10b5-1 Arrangement Terminated	true
Termination Date	8/28/23
Aggregate Available	442,576	442,576
Olivia Ware [Member]
Trading Arrangements, by Individual
Name	Olivia Ware
Title	Director
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	8/31/23
Arrangement Duration	365 days
Aggregate Available	9,593	9,593

The Company and Summary of Si_2

The Company and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying condensed consolidated financial statements are unaudited, and reflect all adjustments which are, in the opinion of management, of a normal recurring nature and necessary for a fair statement of the results for the interim periods presented. Our condensed consolidated balance sheet for the year ended December 31, 2022 included herein was derived from audited consolidated financial statements, but does not include all disclosures including notes required by U.S. GAAP. The interim results presented herein are not necessarily indicative of the results of operations that may be expected for the full fiscal year ending December 31, 2023, or any other future period. Our unaudited condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements contained in our FY2022 10-K. Our condensed consolidated financial statements include our accounts and those of our wholly-owned subsidiaries, and have been prepared in conformity with U.S. GAAP. All intercompany transactions have been eliminated.
Reclassification	ReclassificationAt the beginning of 2023, we changed our presentation of internal-use software where approximately $8.3 million has been reclassified from property and equipment, net into intangible assets, net.
Use of Estimates & Risks and Uncertainties	Use of Estimates & Risks and Uncertainties The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities in the condensed consolidated financial statements and accompanying notes. These estimates form the basis for judgments we make about the carrying values of our assets and liabilities, which are not readily apparent from other sources. We base our estimates and judgments on historical information and on various other assumptions that we believe are reasonable under the circumstances. U.S. GAAP requires us to make estimates and judgments in several areas, including, but not limited to, the incremental borrowing rate used to measure operating lease and finance lease liabilities, the recoverability of goodwill and long-lived assets, useful lives associated with property and equipment and intangible assets, the period of benefit associated with deferred costs, revenue recognition (including the timing of satisfaction of performance obligations, estimating variable consideration, estimating stand-alone selling prices of promised goods and services, and allocation of transaction price to performance obligations), deferred revenue classification, accruals for clinical trial costs, valuation and assumptions underlying stock-based compensation and other equity instruments, and income taxes. As of the date of issuance of these condensed consolidated financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates, judgments or revise the carrying value of our assets or liabilities. These estimates may change as new events occur and additional information is obtained, and are recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to our condensed consolidated financial statements.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The recent accounting pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and we do not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on our present or future financial statements.

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue	The following table presents our revenue disaggregated by timing of transfer of goods or service: Three Months Ended September 30, 2023 Nine Months Ended September 30, 2023 Transferred Transferred (in thousands) at a point in time over time Total at a point in time over time Total Product revenue $ 54,109 $ — $ 54,109 $ 154,160 $ — $ 154,160 Service revenue — 2,664 2,664 59 9,883 9,942 Collaboration revenue — 3 3 — 139 139 Total revenue $ 54,109 $ 2,667 $ 56,776 $ 154,219 $ 10,022 $ 164,241 Three Months Ended September 30, 2022 Nine Months Ended September 30, 2022 Transferred Transferred (in thousands) at a point in time over time Total at a point in time over time Total Product revenue $ 26,081 $ — $ 26,081 $ 72,401 $ — $ 72,401 Service revenue 121 1,843 1,964 360 3,686 4,046 Collaboration revenue — 970 970 — 6,197 6,197 Total revenue $ 26,202 $ 2,813 $ 29,015 $ 72,761 $ 9,883 $ 82,644 Product Revenue Our product revenue breakdown is summarized below: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Product: RHA ® Collection of dermal fillers $ 32,133 $ 26,081 $ 94,180 $ 72,401 DAXXIFY ® 21,976 — 59,980 — Total product revenue $ 54,109 $ 26,081 $ 154,160 $ 72,401
Schedule of Contract with Customer, Contract Asset, Contract Liability, and Receivable	Accounts receivables and contract liabilities from contracts with our product customers are as follows: September 30, December 31, (in thousands) 2023 2022 Accounts receivables: Accounts receivable, net $ 22,661 $ 10,966 Total accounts receivable, net $ 22,661 $ 10,966 Contract liabilities: Deferred revenue, current $ 398 $ 705 Total contract liabilities $ 398 $ 705 Accounts receivable from contracts with our service customers are as follows: September 30, December 31, (in thousands) 2023 2022 Accounts receivable: Accounts receivable, net $ 53 $ 59 Total accounts receivable, net $ 53 $ 59 Accounts receivables and contract liabilities from contracts with our collaboration customers are as follows: September 30, December 31, (in thousands) 2023 2022 Accounts receivables: Accounts receivable, net — Fosun $ 2,700 $ 315 Total accounts receivable, net $ 2,700 $ 315 Contract liabilities: Deferred revenue, current — Viatris $ 4,973 $ 6,162 Total contract liabilities, current $ 4,973 $ 6,162 Deferred revenue, non-current — Viatris $ 43,340 $ 40,600 Deferred revenue, non-current — Fosun 40,975 37,977 Total contract liabilities, non-current $ 84,315 $ 78,577 Changes in our contract liabilities from contracts with our collaboration revenue customers for the nine months ended September 30, 2023 are as follows: (in thousands) Balance on December 31, 2022 $ 84,739 Revenue recognized (139) Billings and adjustments, net 4,688 Balance on September 30, 2023 $ 89,288

Restructuring (Tables)

Restructuring (Tables)	9 Months Ended
	Sep. 30, 2023
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Charges	A summary of our restructuring charges included within our condensed consolidated statement of operations for the three and nine months ended September 30, 2023 were as follows: (in thousands) Goodwill impairment $ 77,175 Intangible asset impairment 16,007 Selling, general and administrative 732 Research and development 1,293 Total restructuring charges $ 95,207
Schedule of Severance and Personnel Liabilities	A summary of severance and personnel liabilities, included within accruals and other current liabilities on the condensed consolidated balance sheet, is as follows: (in thousands) Balance on December 31, 2022 $ — Severance and other personnel costs 1,432 Cash payment during the period — Balance on September 30, 2023 (1) $ 1,432

Cash Equivalents and Short-Te_2

Cash Equivalents and Short-Term Investments (Tables)	9 Months Ended
	Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Schedule of Available-for-sale Securities	The following table summarizes our cash equivalents and short-term investments: September 30, 2023 December 31, 2022 (in thousands) Adjusted Cost Gain Loss Fair Value Adjusted Cost Losses Fair Value U.S. treasury securities $ 197,446 $ 4 $ — $ 197,450 $ 109,984 $ (228) $ 109,756 Commercial paper 55,162 — (17) 55,145 80,946 — 80,946 Money market funds 29,416 — — 29,416 85,206 — 85,206 Corporate bonds — — — — 41,186 (146) 41,040 U.S. government agency obligations — — — — 4,480 — 4,480 Total cash equivalents and short-term investments $ 282,024 $ 4 $ (17) $ 282,011 $ 321,802 $ (374) $ 321,428 Classified as: Cash equivalents $ 161,085 $ 89,686 Short-term investments 120,926 231,742 Total cash equivalents and short-term investments $ 282,011 $ 321,428

Goodwill and intangible Asset_2

Goodwill and intangible Assets, net (Tables)	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The changes in the carrying amount of goodwill by reporting unit during the nine months ended September 30, 2023 was as follows: (in thousands) Product Service Total Balance at December 31, 2022 $ — $ 77,175 $ 77,175 Impairment — (77,175) (77,175) Balance at September 30, 2023 $ — $ — $ —
Schedule of Acquired Finite-lived Intangible Assets by Major Class	The following table sets forth the major categories of intangible assets and the weighted-average remaining useful lives for those assets that are not already fully amortized: September 30, 2023 (in thousands, except for in years) Weighted Average Remaining Useful Lives Gross Carrying Amount Accumulated Amortization Accumulated Impairment Net Carrying Amount Distribution rights 4.5 $ 32,334 $ (22,518) $ — $ 9,816 Internally developed technology 1.7 8,918 (4,293) (3,972) 653 Other software 0.3 879 (841) — 38 Acquired developed technology 0.0 16,200 (6,525) (9,675) — Customer relationships 0.0 10,300 (7,940) (2,360) — Total intangible assets $ 68,631 $ (42,117) $ (16,007) $ 10,507 December 31, 2022 (in thousands, except for in years) Weighted Average Remaining Useful Lives Gross Carrying Amount Accumulated Amortization Net Carrying Amount Acquired developed technology 4.2 $ 35,800 $ (24,325) $ 11,475 Distribution rights 1.4 32,334 (20,882) 11,452 Internally developed technology 2.4 8,062 (2,271) 5,791 Customer relationships 1.6 10,300 (6,223) 4,077 Other software 1.8 3,166 (1,592) 1,574 Development in progress N/A 975 — 975 Total intangible assets $ 90,637 $ (55,293) $ 35,344
Schedule of Acquired Indefinite-lived Intangible Assets by Major Class	The following table sets forth the major categories of intangible assets and the weighted-average remaining useful lives for those assets that are not already fully amortized: September 30, 2023 (in thousands, except for in years) Weighted Average Remaining Useful Lives Gross Carrying Amount Accumulated Amortization Accumulated Impairment Net Carrying Amount Distribution rights 4.5 $ 32,334 $ (22,518) $ — $ 9,816 Internally developed technology 1.7 8,918 (4,293) (3,972) 653 Other software 0.3 879 (841) — 38 Acquired developed technology 0.0 16,200 (6,525) (9,675) — Customer relationships 0.0 10,300 (7,940) (2,360) — Total intangible assets $ 68,631 $ (42,117) $ (16,007) $ 10,507 December 31, 2022 (in thousands, except for in years) Weighted Average Remaining Useful Lives Gross Carrying Amount Accumulated Amortization Net Carrying Amount Acquired developed technology 4.2 $ 35,800 $ (24,325) $ 11,475 Distribution rights 1.4 32,334 (20,882) 11,452 Internally developed technology 2.4 8,062 (2,271) 5,791 Customer relationships 1.6 10,300 (6,223) 4,077 Other software 1.8 3,166 (1,592) 1,574 Development in progress N/A 975 — 975 Total intangible assets $ 90,637 $ (55,293) $ 35,344
Summary of Finite-lived Intangible Assets Amortization Expense	The detail breakdown of the amortization expenses on the condensed consolidated statements of operations and comprehensive loss were summarized as below: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Depreciation and amortization $ 1,320 $ 3,513 $ 5,459 $ 10,538 Selling, general and administrative 429 644 2,998 1,931 Total intangible asset amortization $ 1,749 $ 4,157 $ 8,457 $ 12,469
Schedule of Finite-lived Intangible Assets, Future Amortization Expense	Based on the amount of intangible assets as of September 30, 2023, the expected amortization expense for each of the next five fiscal years was as follows: Year Ending December 31, (in thousands) 2023 remaining three months $ 700 2024 2,567 2025 2,333 2026 2,181 2027 2,181 2028 and thereafter 545 Total $ 10,507

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2023
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories consist of the following: September 30, December 31, (in thousands) 2023 2022 Raw materials $ 2,894 $ 505 Work in process 13,490 4,933 Finished goods 29,830 12,887 Total inventories $ 46,214 $ 18,325

Accruals and other current li_2

Accruals and other current liabilities (Tables)	9 Months Ended
	Sep. 30, 2023
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accruals and other current liabilities consists of the following: September 30, December 31, (in thousands) 2023 2022 Accruals related to: Compensation (1) $ 26,027 $ 28,014 Inventories 8,376 2,312 Selling, general and administrative 7,711 9,681 Research and development 5,047 9,012 Clinical trials 872 1,863 Interest expense 625 1,912 Other current liabilities 4,835 6,563 Total accruals and other current liabilities $ 53,493 $ 59,357 (1) Restructuring related severance and personnel liabilities included within accruals and other current liabilities on the condensed consolidated balance sheets were discussed in Note 3 .

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2023
Leases [Abstract]
Schedule of Lease Costs	The operating and finance lease costs are summarized as follows: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Finance lease: Amortization of finance lease right-of-use asset (1) $ 3,297 $ 3,344 $ 6,965 $ 4,502 Interest on finance lease liability 270 348 1,278 2,607 Variable lease cost (2) 62 1,134 436 1,375 Total finance lease costs 3,629 4,826 8,679 8,484 Operating leases: Operating lease cost 3,138 2,223 9,657 6,669 Variable lease cost (3) 534 423 1,589 1,288 Total operating lease costs 3,672 2,646 11,246 7,957 Total lease costs $ 7,301 $ 7,472 $ 19,925 $ 16,441 (1) Amortization of the finance lease right-of-use asset started to be capitalized into inventories on the condensed consolidated balance sheets in the second quarter of 2023 as a result of the FDA approval of the PAS of the ABPS manufacturing facility. (2) Variable finance lease cost includes validation, qualification, materials, and other related services which are not included in the lease liabilities and are expensed as incurred. (3) Variable operating lease cost includes management fees, common area maintenance, property taxes, insurance and parking fees, which are not included in the lease liabilities and are expensed as incurred.
Schedule of Finance Lease, Liability Maturities	As of September 30, 2023, maturities of our lease liabilities are as follows: (in thousands) Finance Lease Operating Leases Total Year Ending December 31, 2023 remaining three months $ 5,647 $ 5,065 $ 10,712 2024 3,102 10,491 13,593 2025 — 10,854 10,854 2026 — 11,185 11,185 2027 — 4,536 4,536 2028 and thereafter — 28,586 28,586 Total lease payments 8,749 70,717 79,466 Less imputed interest (139) (19,779) (19,918) Present value of lease payments $ 8,610 $ 50,938 $ 59,548 Our lease contracts do not provide readily determinable implicit rates, as such, we used the estimated incremental borrowing rate based on the information available at the adoption, commencement, or remeasurement date. As of September 30, 2023, weighted-average remaining lease terms and discount rates are as follows: Finance Leases Operating Leases Weighted-average remaining lease term (years) 2.5 8.4 Weighted-average discount rate 10.7 % 10.0 %
Schedule of Operating Lease, Liability Maturities	As of September 30, 2023, maturities of our lease liabilities are as follows: (in thousands) Finance Lease Operating Leases Total Year Ending December 31, 2023 remaining three months $ 5,647 $ 5,065 $ 10,712 2024 3,102 10,491 13,593 2025 — 10,854 10,854 2026 — 11,185 11,185 2027 — 4,536 4,536 2028 and thereafter — 28,586 28,586 Total lease payments 8,749 70,717 79,466 Less imputed interest (139) (19,779) (19,918) Present value of lease payments $ 8,610 $ 50,938 $ 59,548 Our lease contracts do not provide readily determinable implicit rates, as such, we used the estimated incremental borrowing rate based on the information available at the adoption, commencement, or remeasurement date. As of September 30, 2023, weighted-average remaining lease terms and discount rates are as follows: Finance Leases Operating Leases Weighted-average remaining lease term (years) 2.5 8.4 Weighted-average discount rate 10.7 % 10.0 %
Schedule of Supplemental Cash Flow Information	Supplemental cash flow information related to the leases was as follows: Nine Months Ended September 30, (in thousands) 2023 2022 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 6,264 $ 6,259 Operating cash flows from finance lease $ 1,280 $ 2,541 Financing cash flows from finance lease $ 15,513 $ 5,000 Right-of-use assets obtained in exchange for lease liabilities Finance lease $ 23,781 $ 14,523 Operating leases (1) $ 22,694 $ — (1) In September 2023, the Expansion Premises and Second Expansion Premises commenced resulting in recognition of $22.7 million right-of-use asset and $16.2 million lease liability.

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Schedule of Convertible Debt	The following table provides information regarding our debt: September 30, December 31, (in thousands) 2023 2022 2027 Notes, non-current $ 287,500 $ 287,500 Less: Unamortized debt issuance costs (4,609) (5,587) Carrying amount of the 2027 Notes 282,891 281,913 Notes Payable, current 1,250 — Notes Payable, non-current 148,750 100,000 Less: Unamortized debt discount (2,976) (1,347) Less: Unamortized debt issuance costs (1,564) (1,192) Carrying amount of Notes Payable 145,460 97,461 Total debt $ 428,351 $ 379,374 Interest expense relating to our debt in the condensed consolidated statements of operations and comprehensive loss are summarized as follows: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Contractual interest expense $ 3,830 $ 3,454 $ 10,620 $ 8,425 Amortization of debt issuance costs 447 441 1,310 1,190 Amortization of debt discount 157 98 329 183 Total interest expense $ 4,434 $ 3,993 $ 12,259 $ 9,798

Stockholders_ Equity and Stoc_2

Stockholders’ Equity and Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Schedule of Common Stock Equivalents Excluded From Computation of Diluted Net Income (Loss) Per Share	Common stock equivalents that were excluded from the computation of diluted net loss per share are presented below: September 30, 2023 2022 Convertible senior notes 8,878,938 8,878,938 Outstanding stock options 3,886,868 4,957,025 Unvested RSUs and PSUs 3,266,886 2,690,816 Unvested RSAs and PSAs 949,059 2,339,999 Shares of common stock expected to be purchased on December 31st under the 2014 ESPP 118,258 188,715
Schedule of Stock-based Compensation Expense	The following table summarizes our stock-based compensation expense by line item in our condensed consolidated statements of operations and comprehensive loss: (in thousands) Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Selling, general and administrative $ 8,599 $ 13,245 $ 31,042 $ 27,937 Research and development 1,688 4,742 7,926 13,676 Cost of product revenue (exclusive of depreciation and amortization) 358 — 1,306 — Total stock-based compensation expense, net of amounts capitalized 10,645 17,987 40,274 41,613 Capitalized stock-based compensation 1,212 566 2,901 682 Total stock-based compensation expense $ 11,857 $ 18,553 $ 43,175 $ 42,295

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Financial Instruments	The following table summarizes, for assets and liabilities measured at fair value, the respective fair value and the classification by level of input within the fair value hierarchy. September 30, 2023 (in thousands) Fair Value Level 1 Level 2 Level 3 Assets U.S. treasury securities $ 197,450 $ 197,450 $ — $ — Money market funds 29,416 29,416 — — Commercial paper 55,145 — 55,145 — Total assets measured at fair value $ 282,011 $ 226,866 $ 55,145 $ — December 31, 2022 (in thousands) Fair Value Level 1 Level 2 Level 3 Assets U.S. treasury securities $ 109,756 $ 109,756 $ — $ — Money market funds 85,206 85,206 — — U.S. government agency obligations 4,480 4,480 — — Commercial paper 80,946 — 80,946 — Corporate bonds 41,040 — 41,040 — Total assets measured at fair value $ 321,428 $ 199,442 $ 121,986 $ —

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
Schedule of Reconciliation of Segment Revenue to Consolidated Revenue	Reconciliation of Segment Revenue to Consolidated Revenue Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Revenue: Product Segment $ 54,112 $ 27,051 $ 154,299 $ 78,598 Service Segment 2,664 1,964 9,942 4,046 Total revenue $ 56,776 $ 29,015 $ 164,241 $ 82,644
Schedule of Reconciliation of Segment Loss From Operations to Consolidated Loss From Operations	Reconciliation of Segment Loss from Operations to Consolidated Loss from Operations Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Loss from operations: Product Segment $ (9,032) $ (32,100) $ (41,097) $ (82,020) Service Segment (1) (98,169) (4,423) (110,234) (13,956) Corporate and other expenses (32,092) (40,961) (111,493) (101,571) Total loss from operations $ (139,293) $ (77,484) $ (262,824) $ (197,547) (1) For the three and nine months ended September 30, 2023, loss from operations for the Service Segment included an impairment loss of $93.2 million as discussed in Note 5

The Company and Summary of Si_3

The Company and Summary of Significant Accounting Policies (Details) - USD ($)		3 Months Ended		9 Months Ended
	May 10, 2022	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Debt Instrument [Line Items]
Net loss		$ 141,176,000	$ 84,693,000	$ 268,287,000	$ 210,470,000
Accumulated deficit		2,022,661,000		2,022,661,000		$ 1,754,374,000
Working capital surplus		306,400,000		306,400,000
Cash, cash equivalents and investments		300,200,000		300,200,000
Internally developed technology
Debt Instrument [Line Items]
Net into intangible assets		$ 8,300,000		8,300,000
ATM Offering, 2022 Plan
Debt Instrument [Line Items]
Stock issuance sales agreement, authorized offering price, maximum	$ 150,000,000			$ 47,200,000

Revenue - Schedule of Revenues

Revenue - Schedule of Revenues Disaggregated by Timing of Transfer of Goods or Services (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue	$ 56,776	$ 29,015	$ 164,241	$ 82,644
Transferred at a point in time
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue	54,109	26,202	154,219	72,761
Transferred at over Time
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue	2,667	2,813	10,022	9,883
Product revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue	54,109	26,081	154,160	72,401
Product revenue | Transferred at a point in time
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue	54,109	26,081	154,160	72,401
Product revenue | Transferred at over Time
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue	0	0	0	0
RHA® Collection of dermal fillers
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue	32,133	26,081	94,180	72,401
DAXXIFY®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue	21,976	0	59,980	0
Service revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue	2,664	1,964	9,942	4,046
Service revenue | Transferred at a point in time
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue	0	121	59	360
Service revenue | Transferred at over Time
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue	2,664	1,843	9,883	3,686
Collaboration revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue	3	970	139	6,197
Collaboration revenue | Transferred at a point in time
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue	0	0	0	0
Collaboration revenue | Transferred at over Time
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue	$ 3	$ 970	$ 139	$ 6,197

Revenue - Schedule of Receivabl

Revenue - Schedule of Receivables and Contract Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Contract liabilities:
Deferred revenue, current	$ 5,371	$ 6,867
Product revenue
Accounts receivables:
Total accounts receivable, net	22,661	10,966
Contract liabilities:
Deferred revenue, current	398	705
Service revenue
Accounts receivables:
Total accounts receivable, net	$ 53	$ 59

Revenue - Narrative (Details)

Revenue - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Non-refundable upfront payment	$ 89,288,000		$ 89,288,000		$ 84,739,000
Remaining performance obligation	41,000,000		41,000,000
Contract with customer, liability, revenue recognized			139,000
Viatris
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue recognition annual sales			$ 50,000,000
Revenue recognition annual sales of maturity period			4 years
Fosun
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent payments	222,500,000		$ 222,500,000
Remaining performance obligation	38,000,000		38,000,000
Fosun | Development Services
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	100,000		100,000
Viatris
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Non-refundable upfront payment	60,000,000		60,000,000
Contingent payments	70,000,000		70,000,000
Revenue maximum for receipt of tiered milestone payments			225,000,000
Remaining performance obligation	44,200,000		44,200,000
Viatris | Development Services
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	$ 0	$ 1,000,000	$ 0	$ 6,200,000
Fosun
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract with customer, liability, revenue recognized		$ 0		$ 0

Revenue - Schedule of Contract

Revenue - Schedule of Contract Liabilities from Contracts (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Contract liabilities:
Total contract liabilities, current	$ 5,371	$ 6,867
Total contract liabilities, non-current	84,315	78,577
Fosun
Accounts receivables:
Total accounts receivable, net	2,700	315
Contract liabilities:
Total contract liabilities, non-current	40,975	37,977
Viatris
Contract liabilities:
Total contract liabilities, current	4,973	6,162
Total contract liabilities, non-current	$ 43,340	$ 40,600

Revenue - Schedule of Changes i

Revenue - Schedule of Changes in Our Contract Liabilities from Contracts (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($)
Contract With Customer Asset and Liability Roll Forward [Abstract]
Beginning balance	$ 84,739
Revenue recognized	(139)
Billings and adjustments, net	4,688
Ending balance	$ 89,288

Restructuring - Narrative (Deta

Restructuring - Narrative (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 1,432
Service Segment
Restructuring Cost and Reserve [Line Items]
Restructuring charges	95,207
Restructuring expected cost	$ 3,000

Restructuring - Schedule of Res

Restructuring - Schedule of Restructuring Charges (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($)
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	$ 1,432
Service Segment
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	95,207
Goodwill impairment | Service Segment
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	77,175
Intangible asset impairment | Service Segment
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	16,007
Selling, general and administrative | Service Segment
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	732
Research and development | Service Segment
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	$ 1,293

Restructuring - Schedule of Sev

Restructuring - Schedule of Severance and Personnel Liabilities (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($)
Restructuring Reserve [Roll Forward]
Balance on December 31, 2022	$ 0
Severance and other personnel costs	1,432
Cash payment during the period	0
Balance on September 30, 2023	$ 1,432

Cash Equivalents and Short-Te_3

Cash Equivalents and Short-Term Investments - Schedule of Available-for-sale Securities (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]
Adjusted Cost	$ 282,024	$ 321,802
Gain	4
Loss	(17)	(374)
Fair Value	282,011	321,428
Cash equivalents
Debt Securities, Available-for-sale [Line Items]
Fair Value	161,085	89,686
Short-term investments
Debt Securities, Available-for-sale [Line Items]
Fair Value	120,926	231,742
U.S. treasury securities
Debt Securities, Available-for-sale [Line Items]
Adjusted Cost	197,446	109,984
Gain	4
Loss	0	(228)
Fair Value	197,450	109,756
Commercial paper
Debt Securities, Available-for-sale [Line Items]
Adjusted Cost	55,162	80,946
Gain	0
Loss	(17)	0
Fair Value	55,145	80,946
Money market funds
Debt Securities, Available-for-sale [Line Items]
Adjusted Cost	29,416	85,206
Gain	0
Loss	0	0
Fair Value	29,416	85,206
Corporate bonds
Debt Securities, Available-for-sale [Line Items]
Adjusted Cost	0	41,186
Gain	0
Loss	0	(146)
Fair Value	0	41,040
U.S. government agency obligations
Debt Securities, Available-for-sale [Line Items]
Adjusted Cost	0	4,480
Gain	0
Loss	0	0
Fair Value	$ 0	$ 4,480

Goodwill and intangible Asset_3

Goodwill and intangible Assets, net- Narrative (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Goodwill [LineItems]
Goodwill and intangible asset impairment		$ 93,182	$ 0
Accumulated Impairment	$ 147,000	147,000		$ 69,800
Service Segment
Goodwill [LineItems]
Goodwill and intangible asset impairment	77,200	77,200
Impairment of finite-lived intangible assets	$ 16,000	$ 16,000

Goodwill and intangible Asset_4

Goodwill and intangible Assets, net - Schedule of Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Goodwill [Roll Forward]
Beginning Balance			$ 77,175
Impairment	$ (77,175)	$ 0	(77,175)	$ 0
Ending Balance	0		0
Product Segment
Goodwill [Roll Forward]
Beginning Balance			0
Impairment			0
Ending Balance	0		0
Service Segment
Goodwill [Roll Forward]
Beginning Balance			77,175
Impairment			(77,175)
Ending Balance	$ 0		$ 0

Goodwill and intangible Asset_5

Goodwill and intangible Assets, net - Schedule of Acquired Finite-lived and Indefinite-lived Intangible Assets by Major Class (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Acquired Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 68,631	$ 90,637
Accumulated Amortization	(42,117)	(55,293)
Accumulated Impairment	(16,007)
Total	10,507
Net Carrying Amount	$ 10,507	35,344
Development in progress
Acquired Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets		$ 975
Distribution rights
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Remaining Useful Lives (in years)	4 years 6 months	1 year 4 months 24 days
Finite-lived intangible assets, gross	$ 32,334	$ 32,334
Accumulated Amortization	(22,518)	(20,882)
Accumulated Impairment	0
Total	$ 9,816	$ 11,452
Internally developed technology
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Remaining Useful Lives (in years)	1 year 8 months 12 days	2 years 4 months 24 days
Finite-lived intangible assets, gross	$ 8,918	$ 8,062
Accumulated Amortization	(4,293)	(2,271)
Accumulated Impairment	(3,972)
Total	$ 653	$ 5,791
Other software
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Remaining Useful Lives (in years)	3 months 18 days	1 year 9 months 18 days
Finite-lived intangible assets, gross	$ 879	$ 3,166
Accumulated Amortization	(841)	(1,592)
Accumulated Impairment	0
Total	$ 38	$ 1,574
Acquired developed technology
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Remaining Useful Lives (in years)	0 years	4 years 2 months 12 days
Finite-lived intangible assets, gross	$ 16,200	$ 35,800
Accumulated Amortization	(6,525)	(24,325)
Accumulated Impairment	(9,675)
Total	$ 0	$ 11,475
Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Remaining Useful Lives (in years)	0 years	1 year 7 months 6 days
Finite-lived intangible assets, gross	$ 10,300	$ 10,300
Accumulated Amortization	(7,940)	(6,223)
Accumulated Impairment	(2,360)
Total	$ 0	$ 4,077

Goodwill and intangible Asset_6

Goodwill and intangible Assets, net - Condensed Consolidated Statements of Operations and Comprehensive Loss (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Acquired Finite-Lived Intangible Assets [Line Items]
Total intangible asset amortization	$ 1,749	$ 4,157	$ 8,457	$ 12,469
Depreciation and amortization
Acquired Finite-Lived Intangible Assets [Line Items]
Total intangible asset amortization	1,320	3,513	5,459	10,538
Selling, general and administrative
Acquired Finite-Lived Intangible Assets [Line Items]
Total intangible asset amortization	$ 429	$ 644	$ 2,998	$ 1,931

Goodwill and intangible Asset_7

Goodwill and intangible Assets, net - Schedule of Finite-lived Intangible Assets, Future Amortization Expense (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2023 remaining three months	$ 700
2024	2,567
2025	2,333
2026	2,181
2027	2,181
2028 and thereafter	545
Total	$ 10,507

Inventories - Schedule of Inven

Inventories - Schedule of Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 2,894	$ 505
Work in process	13,490	4,933
Finished goods	29,830	12,887
Total inventories	$ 46,214	$ 18,325

Accruals and other current li_3

Accruals and other current liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Compensation	$ 26,027	$ 28,014
Inventories	8,376	2,312
Selling, general and administrative	7,711	9,681
Research and development	5,047	9,012
Clinical trials	872	1,863
Interest expense	625	1,912
Other current liabilities	4,835	6,563
Total accruals and other current liabilities	$ 53,493	$ 59,357

Leases - Narrative (Details)

Leases - Narrative (Details) $ in Thousands	1 Months Ended	9 Months Ended
	Apr. 30, 2021 option_to_extend_lease_term	Sep. 30, 2023 USD ($) option_to_extend_lease_term	Jan. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	May 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Lessee, Lease, Description [Line Items]
Number of options to renew (or more) | option_to_extend_lease_term		1
Term of written notice		18 months
Purchase obligation, to be paid, year one						$ 30,000
Purchase obligation, to be paid, year two						30,000
Purchase obligation, to be paid, year three						$ 30,000
Purchase obligation eliminated, year one			$ 23,900		$ 30,000
Purchase obligation eliminated, year two					30,000
Purchase obligation eliminated, year three					$ 30,000
Collaborative agreement, number of extension periods | option_to_extend_lease_term	1
Other non-current assets		$ 235		$ 1,687
Other commitment, to be paid, year one		10,900
Other commitment, to be paid, year two		15,900
Other commitment, to be paid, year three		18,300
Other commitment, to be paid, year four		25,300
Other commitment, to be paid, year five		29,500
Other commitment, to be paid, after year five		134,500
PCI Supply Agreement
Lessee, Lease, Description [Line Items]
Collaborative agreement, contractual period	3 years
Other non-current assets		$ 30,900
Minimum
Lessee, Lease, Description [Line Items]
Extended term of lease		7 years
Maximum
Lessee, Lease, Description [Line Items]
Extended term of lease		14 years

Leases - Schedule of Lease Cost

Leases - Schedule of Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Finance lease:
Amortization of finance lease right-of-use asset	$ 3,297	$ 3,344	$ 6,965	$ 4,502
Interest on finance lease liability	270	348	1,278	2,607
Variable lease cost	62	1,134	436	1,375
Total finance lease costs	3,629	4,826	8,679	8,484
Operating leases:
Operating lease cost	3,138	2,223	9,657	6,669
Variable lease cost	534	423	1,589	1,288
Total operating lease costs	3,672	2,646	11,246	7,957
Total lease costs	$ 7,301	$ 7,472	$ 19,925	$ 16,441

Leases - Schedule of Finance Le

Leases - Schedule of Finance Lease and Operating Lease Liability Maturities (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Finance Lease
2023 remaining three months	$ 5,647
2024	3,102
2025	0
2026	0
2027	0
2028 and thereafter	0
Total lease payments	8,749
Less imputed interest	(139)
Present value of lease payments	8,610
Operating Leases
2023 remaining three months	5,065
2024	10,491
2025	10,854
2026	11,185
2027	4,536
2028 and thereafter	28,586
Total lease payments	70,717
Less imputed interest	(19,779)
Present value of lease payments	50,938
Total
2023 remaining three months	10,712
2024	13,593
2025	10,854
2026	11,185
2027	4,536
2028 and thereafter	28,586
Total lease payments	79,466
Less imputed interest	(19,918)
Present value of lease payments	$ 59,548

Leases - Schedule of Remaining

Leases - Schedule of Remaining Lease terms and Discount Rates (Details)	Sep. 30, 2023
Finance Leases
Weighted-average remaining lease term (year)	2 years 6 months
Weighted-average discount rate (percent)	10.70%
Operating Leases
Weighted-average remaining lease term (year)	8 years 4 months 24 days
Weighted average discount rate (percent)	10%

Leases - Schedule of Supplement

Leases - Schedule of Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Cash Flow, Lessee [Abstract]
Operating cash flows from operating leases	$ 6,264	$ 6,259
Operating cash flows from finance lease	1,280	2,541
Financing cash flows from finance lease	15,513	5,000
Right-of-use assets obtained in exchange for lease liabilities
Finance lease	23,781	14,523
Operating leases	22,694	$ 0
Operating lease right-of-use assets	54,810		$ 39,223
Present value of lease payments	50,938
Expansion Premises and Second Expansion Premises
Right-of-use assets obtained in exchange for lease liabilities
Operating lease right-of-use assets	22,700
Present value of lease payments	$ 16,200

Debt - Schedule of Convertible

Debt - Schedule of Convertible Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Carrying amount of Notes Payable	$ 428,351	$ 379,374
Total debt	428,351	379,374
Convertible Debt
Debt Instrument [Line Items]
Less: Unamortized debt issuance costs	(1,564)	(1,192)
Carrying amount of Notes Payable	145,460	97,461
Notes Payable, current	1,250	0
Notes Payable, non-current	148,750	100,000
Less: Unamortized debt discount	(2,976)	(1,347)
Total debt	145,460	97,461
2027 Notes | Convertible Debt
Debt Instrument [Line Items]
2027 Notes, non-current	287,500	287,500
Less: Unamortized debt issuance costs	(4,609)	(5,587)
Carrying amount of Notes Payable	282,891	281,913
Total debt	$ 282,891	$ 281,913

Debt - Schedule of Interest Exp

Debt - Schedule of Interest Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Debt Disclosure [Abstract]
Contractual interest expense	$ 3,830	$ 3,454	$ 10,620	$ 8,425
Amortization of debt issuance costs	447	441	1,310	1,190
Amortization of debt discount	157	98	329	183
Total interest expense	$ 4,434	$ 3,993	$ 12,259	$ 9,798

Debt - Convertible Senior Notes

Debt - Convertible Senior Notes (Details) - 2027 Notes - Convertible Debt		1 Months Ended
	Feb. 29, 2020 USD ($) $ / shares	Feb. 29, 2020 USD ($) trading_day businessDay $ / shares
Debt Instrument [Line Items]
Principal amount | $	$ 287,500,000	$ 287,500,000
Stated percentage	1.75%	1.75%
Net proceeds | $		$ 278,300,000
Threshold trading days		20
Threshold consecutive trading days		30
Threshold percentage of stock price trigger		130%
Conversion ratio	0.0308804
Conversion price (in dollars per share) | $ / shares	$ 32.38	$ 32.38
Redemption price, percentage		100%
Debt Conversion Terms One
Debt Instrument [Line Items]
Threshold trading days		20
Threshold consecutive trading days		30
Threshold percentage of stock price trigger		130%
Debt Conversion Terms Two
Debt Instrument [Line Items]
Threshold trading days | businessDay		5
Threshold consecutive trading days		10
Threshold percentage of stock trading price		98%

Debt - Capped Call Transactions

Debt - Capped Call Transactions (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions		1 Months Ended
	Feb. 10, 2020	Feb. 29, 2020
Debt Instrument [Line Items]
Payment of capped call transactions		$ 28.9
Price cap (in dollars per share)		$ 48.88
Premium percentage over sale price	100%
Number of shares subject to anti-dilution adjustments (in shares)		8.9
2027 Notes | Convertible Debt
Debt Instrument [Line Items]
Conversion price (in dollars per share)		$ 32.38

Debt - Note Purchase Agreement

Debt - Note Purchase Agreement (Details) $ in Thousands		1 Months Ended
	Mar. 18, 2022 USD ($)	Mar. 31, 2022 USD ($)	Sep. 30, 2023 USD ($)	Aug. 31, 2023 USD ($)	Aug. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)
Debt Instrument [Line Items]
Aggregate principal amount			$ 428,351			$ 379,374
Note Purchase Agreement | Notes Payable
Debt Instrument [Line Items]
Principal amount				$ 50,000
Stated percentage		7%
Prepaid fee, percentage	2%
Minimum cash balance maintained	$ 30,000
Minimum net sales requirement	$ 70,000
Debt instrument, debt default, additional interest rate to fixed	2%
Note Purchase Agreement | Notes Payable | Minimum | London Interbank Offered Rate (LIBOR) Swap Rate
Debt Instrument [Line Items]
Variable rate		1.50%
Note Purchase Agreement | Notes Payable | Maximum
Debt Instrument [Line Items]
Debt instrument, trailing twelve months revenue				50,000
Note Purchase Agreement | Notes Payable | Maximum | London Interbank Offered Rate (LIBOR) Swap Rate
Debt Instrument [Line Items]
Variable rate		2.50%
Note Purchase Agreement | Notes Payable | First Tranche
Debt Instrument [Line Items]
Principal amount		$ 100,000			$ 100,000
Note Purchase Agreement | Notes Payable | First Tranche | Debt Instrument Principal Amortization Period One
Debt Instrument [Line Items]
Debt Instrument, Principal Amortization, Payment Percentage	0.025
Note Purchase Agreement | Notes Payable | First Tranche | Debt Instrument Principal Amortization Period Two
Debt Instrument [Line Items]
Debt Instrument, Principal Amortization, Payment Percentage	0.050
Note Purchase Agreement | Notes Payable | First Tranche | Debt Instrument Principal Amortization Period Three
Debt Instrument [Line Items]
Debt Instrument, Principal Amortization, Payment Percentage	0.075
Note Purchase Agreement | Notes Payable | First Tranche | Debt Instrument Principal Amortization Period Four
Debt Instrument [Line Items]
Debt Instrument, Principal Amortization, Payment Percentage	0.100
Note Purchase Agreement | Notes Payable | Second Tranche
Debt Instrument [Line Items]
Principal amount				50,000
Note Purchase Agreement | Notes Payable | Third Tranche
Debt Instrument [Line Items]
Principal amount				$ 150,000
Stated percentage		8.50%
2027 Notes | Notes Payable
Debt Instrument [Line Items]
Aggregate principal amount	$ 90,000

Stockholders_ Equity and Stoc_3

Stockholders’ Equity and Stock-Based Compensation - Narrative (Details) - USD ($)		1 Months Ended	3 Months Ended			4 Months Ended	9 Months Ended
	May 10, 2022	Nov. 30, 2020	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	May 10, 2022	Sep. 30, 2023	Sep. 30, 2022	Jan. 01, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from issuance of common stock							$ 100,183,000	$ 31,814,000
ATM Offering, 2020 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issuance sales agreement, authorized offering price, maximum		$ 125,000,000
Sale of stock, issuance costs, commission, percentage, maximum		3%
Stock issued during period, shares, new issues (in shares)						1,700,000
Proceeds from issuance of common stock						$ 31,600,000
ATM Offering, 2020 Plan | Weighted Average
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (in dollars per share)						$ 18.71
ATM Offering, 2022 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issuance sales agreement, authorized offering price, maximum	$ 150,000,000						$ 47,200,000
Sale of stock, issuance costs, commission, percentage, maximum	3%
Stock issued during period, shares, new issues (in shares)			0	3,200,000	0
Proceeds from issuance of common stock				$ 100,000,000
ATM Offering, 2022 Plan | Weighted Average
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Price per share (in dollars per share)				$ 31.90
2014 EIP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)			4,300,000				4,300,000		3,300,000
2014 IP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)			1,100,000				1,100,000
HintMD Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)			100,000				100,000
Shares underlying stock options granted (in shares)							0
2014 ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)									300,000
Stock Award | 2014 EIP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares underlying stock options granted (in shares)							2,500,000
Share-based Payment Arrangement | 2014 EIP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares underlying stock options granted (in shares)							200,000
Employee Stock Option | 2014 IP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares underlying stock options granted (in shares)							0
Employee Stock | 2014 ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)			1,800,000				1,800,000

Stockholders_ Equity and Stoc_4

Stockholders’ Equity and Stock-Based Compensation -Schedule of Common Stock Equivalents Excluded From Computation of Diluted Net Income (Loss) Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Convertible senior notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares)	8,878,938	8,878,938
Outstanding stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares)	3,886,868	4,957,025
Outstanding stock options | 2014 Employee Stock Purchase Plan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares)	118,258	188,715
Unvested RSUs and PSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares)	3,266,886	2,690,816
Unvested RSAs and PSAs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares)	949,059	2,339,999

Stockholders_ Equity and Stoc_5

Stockholders’ Equity and Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense, net of amounts capitalized	$ 10,645	$ 17,987	$ 40,274	$ 41,613
Capitalized stock-based compensation	1,212	566	2,901	682
Total stock-based compensation expense	11,857	18,553	43,175	42,295
Selling, general and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense, net of amounts capitalized	8,599	13,245	31,042	27,937
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense, net of amounts capitalized	1,688	4,742	7,926	13,676
Cost of product revenue (exclusive of depreciation and amortization)
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense, net of amounts capitalized	$ 358	$ 0	$ 1,306	$ 0

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value of Financial Instruments (Details) - Recurring - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	$ 282,011	$ 321,428
U.S. treasury securities
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	197,450	109,756
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	29,416	85,206
Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	55,145	80,946
U.S. government agency obligations
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		4,480
Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		41,040
Level 1
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	226,866	199,442
Level 1 | U.S. treasury securities
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	197,450	109,756
Level 1 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	29,416	85,206
Level 1 | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0	0
Level 1 | U.S. government agency obligations
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		4,480
Level 1 | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	55,145	121,986
Level 2 | U.S. treasury securities
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0	0
Level 2 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0	0
Level 2 | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	55,145	80,946
Level 2 | U.S. government agency obligations
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		0
Level 2 | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		41,040
Level 3
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0	0
Level 3 | U.S. treasury securities
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0	0
Level 3 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0	0
Level 3 | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	$ 0	0
Level 3 | U.S. government agency obligations
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		0
Level 3 | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		$ 0

Fair Value Measures - Narrative

Fair Value Measures - Narrative (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Convertible debt, fair value disclosures	$ 232.1	$ 288.2

Commitments and Contingencies (

Commitments and Contingencies (Details)	1 Months Ended		9 Months Ended
	Sep. 30, 2020	Jan. 31, 2020 shares	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 30, 2022 patent	Dec. 31, 2021 USD ($)
Loss Contingencies [Line Items]
Purchase obligation, to be paid, year one							$ 30,000,000
Purchase obligation, to be paid, year two							$ 30,000,000
Indemnification liability recorded during the period			$ 0	$ 0
Number of additional alleged patent infringements | patent						3
Estimated litigation liability			0		$ 0
Teoxane Agreement
Loss Contingencies [Line Items]
Issuance of common stock in connection with the teoxane agreement (in shares) | shares		2,500,000
Collaborative agreement, contractual period	10 years
Collaborative agreement, extended contractual period	2 years
Purchase obligation, to be paid, year one			40,000,000
Purchase obligation, to be paid, year two			52,000,000
Minimum expenditures related to commercialization 2023			34,000,000
Minimum expenditures related to commercialization 2024			36,000,000
Botulinum Toxin Research Associates, Inc.
Loss Contingencies [Line Items]
Accrued milestone obligations			$ 15,500,000

Segment Information - Schedule

Segment Information - Schedule of Reconciliation of Segment Revenue to Consolidated Revenue (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) segment	Sep. 30, 2022 USD ($)
Segment Reporting Information [Line Items]
Number of reportable segments | segment			2
Total revenue	$ 56,776	$ 29,015	$ 164,241	$ 82,644
Product Segment
Segment Reporting Information [Line Items]
Total revenue	54,112	27,051	154,299	78,598
Service Segment
Segment Reporting Information [Line Items]
Total revenue	2,664	1,964	$ 9,942	4,046
Intersegment Eliminations
Segment Reporting Information [Line Items]
Number of reportable segments | segment			2
Intersegment Eliminations | Service Segment
Segment Reporting Information [Line Items]
Total revenue	$ 700	$ 400	$ 2,000	$ 900

Segment Information - Schedul_2

Segment Information - Schedule of Reconciliation of Segment Loss from Operations to Consolidated Loss from Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting Information [Line Items]
Total loss from operations	$ (139,293)	$ (77,484)	$ (262,824)	$ (197,547)
Corporate and other expenses
Segment Reporting Information [Line Items]
Total loss from operations	(32,092)	(40,961)	(111,493)	(101,571)
Product Segment | Operating Segments
Segment Reporting Information [Line Items]
Total loss from operations	(9,032)	(32,100)	(41,097)	(82,020)
Service Segment
Segment Reporting Information [Line Items]
Impairment	93,200		93,200
Service Segment | Operating Segments
Segment Reporting Information [Line Items]
Total loss from operations	$ (98,169)	$ (4,423)	$ (110,234)	$ (13,956)